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DETERMINATION OF HEPATITIS В VIRUS MARKERS IN BLOOD DONORS 
Foreword 
The subject of this paper has been deliberately restricted to the problem of de­
termination of hepatitis В virus (HBV) markers in blood donors.This does by no 
means imply that the other possible aetiologic agents of post-transfusion hepati­
tis (PTH),such as cytomegalovirus,Epstein-Barr virus and potentially the most im­
portant agent(s) of "non-B/non-A" PTH do not deserve attention.Quite the opposite, 
one can not hope to approach the solution of the problem of PTH without further 
reserach efforts directed to the characterization and detection of the markers of 
"non-B/non-A" hepatitis agent(s).A possible blueprint and inspiration for this 
work can be found in the experience of Blumberg and his group,the discoverers of 
the Australia antigen,so vividly described by Blumberg himself in his Nobel Prize 
Lecture (1). 
Many other important aspects of HBV infection will also be omitted in this paper; 
some of them,such as the clinical implications of HBV carriership and post-trans­
fusion hepatitis В (PTHB),due to my lack of clinical experience;the others,such 
as a broader discussion of the epidemiology of PTHB (including the subtype deter­
minants of HBV) and the preventive measures,because they have been a subject of 
numerous publications during the last ten years. 
The terminology of HBV markers has gone through a considerable evolution during 
the above-mentioned period.Not having been able to resist temptation of mentio­
ning the name of Australia antigen in the beginning,! shall further adhere to the 
1977 recommendations of the WHO Expert Committee on Viral Hepatitis (2),according 
to which the following symbols should be used for HBV markers: 
нв 
HBsAg 
HBcAg 
HBeAg 
Anti-HBs 
Anti-HBc 
Anti-HBe 
Hepatitis В virus 
Hepatitis В surface antigen 
Hepatitis В core antigen 
Hepatitis В e antigen 
Antibody to hepatitis В surface antigen 
Antibody to hepatitis В core antigen 
Antibody to the hepatitis В e antigen. 
Besides these,the following abbreviations were used in this paper: 
PTH 
PTHB 
ID 
CIEP 
CF 
RPHA 
RIA 
EIA 
Post-transfusion hepatitis 
Post-transfusion hepatitis В 
Immunodiffusion 
Counter-immunoelectrophoresis 
Complement fixation 
Reversed passive haemagglutination 
Radioimmunoassay 
Enzyme-immunoassay. 
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Survey of the problem 
Post-transfjsion hepatitis (PTH) was first recognized as a major problem during 
the Second World War,connected to the wide use of plasma pools.One of the first 
publications referring to PTH was that of Beeson in 1943 (l).This problem was fur­
ther quantified by Kunin (2) and Allen and Sayman (3) who have reported an attack 
-rate of manifest PTH per 100 recipients respectively as 1,9 and 3,0.Some authors, 
such as Creutzfeld (4) reported an incidence of 143і for PTH including a majority 
of non-i eteri с cases. 
However,not until the discovery of HBsAg and its relation to HBV by Blumberg and 
his col laborators,was there a concrete tool for the determination of the presence 
of HBV in donor blood.The first to signal the possible connection between PTHB and 
HBsAg positivity in a single recipient seems to have been Prince (5).0kochi and 
Murakami (6) and Gocke and Kavey (7) were the first to demonstrate unequivocally 
that PTHB can be traced back to the transfusion of HBsAg positive blood.This has 
opened new perspectives,offering a tool that was expected to lead to the elimina­
tion of PTH.Retrospectively,one sees now that this was an over-optimistic expecta-
tion;however,all the massive activity since then has brought us to the realization 
that PTH is not a single aetiologic entity. 
Determination of HBsAg 
Techniques: The first techniques,used by Prince (5) and subsequently others.was dou­
ble immunodiffusion (ID) in agar.This was a rather time-consuming and insensitive 
method;in the beginning,human sera containing anti-HBs (mostly from poly-transfused 
haemophiliacs) were the only source of antibodies.On the other hand,the technique 
offered a simultaneous control of specificity,and enabled the later discovery of 
HBsAg subtypes and that of the HBeAg/anti-HBe system. 
Counter-immunoelectrophoresis (CIEP):The first to describe the application of CIEP 
for the detection of HBsAg were Bedarida et aT. in 1969 (8).However,the modification 
of the technique as described by Pessendorfer et al.(9) gained the greatest populari-
IO 
ty.and was for several years a most widely applied technique for HBsAg determination 
in blood donors.This technique was much faster than ID (about 1,5 hours as compared 
to 24-72 hours for ID);it could simultaneously give - after appropriate modification 
- results for HBsAg and anti-HBs,and it made use of antisera to HBsAg raised in ani-
mals.The first comnercial kits for HBsAg screening widely used were the application 
of this technique.The sensitivity of CIEP was undoubtedly higher than that of ID and 
is estimated to vary by a factor 2-10,depending on the modification and antiserum 
used.One of the disadvantages of both techniques,not quite realized at the height of 
their use was a considerable risk of infection with HBV of the laboratory personnel 
(among other factors.due to the practical non-existence of safety procedures while 
handling wet,contaminated slides with agar gel).This can be illustrated by personal 
observation in mid-1973 showing that 3 of 3 laboratory technicians examined in a lar-
ge North-European blood bank,had evidence of HBV infection (one HBsAg carrier,two 
with anti-HBs),whereas the HBsAg prevalence among blood donors in question was less 
than 0,1% as tested by CIEP. 
At that time there were numerous attempts to advocate alternative techniques for the 
determination of HBsAg,but none of them succeeded in gaining popularity.Some of them 
were¡complement fixation (CF) which was not widely accepted due to the complexity of 
the technique and the problems of standardization,and various agglutination techniques 
using carriers such as charcoal or latex particles coated with anti-HBs.The latter 
technique seemed very promising in the beginning,but failed to gain acceptance due 
to the problems of cross-reactivity with anti-IgG positive sera. 
Passive haemagglutination:There are several principal methods for HBsAg determination 
using erythrocytes from different species as carriers of either purified HBsAg 
(passive haemagglutinationj/yas and Shulman-9) or anti-HBs (reversed passive haema-
gglutination-RPHA.Juji and Yokochi-10). 
The introduction of (later) commercially available techniques of RPHA for determina-
tion of HBsAg marked a new step in screening of blood donors,offering a method simpler, 
more rapid,reproducible and significantly more sensitive than CIEP,that gradually took 
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over the first place from CIEP as a most widely spread technique. 
Our own results of RPHA (Schuurs and Kacaki,11,12) using sheep erythrocytes sensitized 
with sheep anti-HBc will be presented here in some details.The use of sensitive methods 
such as RPHA for detection of HBsAg brought to attention the importance of confirming 
the screening positive results,in view of the emergence of a number of false positives. 
In case of our test (11,12) the majority of false positives were traced back to the 
presence of either Forssman antibody or antibodies against sheep imunoglobulins.The 
solution of this problem was sought in the introduction of absorbent consisting of 
sheep erythrocytes coated with sheep immunoglobulins devoid of anti-HBs activity.The 
serum samples positive in screening tests were absorbed with this reagent and re-tes-
ted in RPHA.Those samples retaining positive reaction were accepted as HBsAg specific 
positives. 
This RPHA was subjected to a multicentre trial in 16 centres in 8 European countries 
and USA on over 41 000 blood donor sera,and the results compared to those obtained 
with simultaneously performed CIEP and CF.The results demonstrated that RPHA was more 
sensitive than CIEP,detecting about 40% more donors positive for HBsAg than the latter, 
and equally sensitive to CF while being far simpler to perform. 
Another test,a microtitre RPHA technique using turkey erythrocytes coated with the 
affinity chromatography-purified horse anti-HBs,was described soon thereafter by 
Cayzer et al (13).This test also became commercially available and its sensitivity 
was shown to be slighly higher than that of the former technique. 
Radioimmunoassay (RIA):Walsh et al.(14) have described in 1970 the first application 
of RIA technique for the detection of HBsAg,using 1 2 5I as a label.Many modifications 
were described thereafter,but the one that gained most in popularity was that of Ling 
and Overby (15),using the principle of the solid-phase sandwich-type RIA.This method 
was shown to be up to 10-fold more sensitive for the detection of HBsAg than the RPHA 
or CF,using serial dilutions of HBsAg.However,a number of screening positive samples 
by this method was shown to be false positive by Prince et al. (16) who were able to 
neutralize by the addition of anti-HBs only 17/81 (21%) os sera positive for HBsAg 
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by RIA,but negative by CIEP.The transfusion of HBsAg specific positive blood caused 
serological evidence of HBV infection or overt PTH in 13/15 recipients,while the trans-
fusion of non-specific positive blood caused such changes in only 1/18 recipients.This 
and other similar findings led to the modification of Ling and Overby's test to its 
present form,with even higher sensitivity,but the specificity of the screening posi-
tive results has to be confirmed by neutralization with anti-HBs and re-testing (17). 
Enzyme-inrnunoassay (EIA):The principle of EIA using a solid-phase sandwich type tech-
nique with the second antibody labelled with horse-radish peroxidase was first appli-
ed to the detection of HBsAg by Wolters et al.in 1976 (18,19).The publications form 
part of this thesis.In the preliminary laboratory phase,strong indications were 
found that the test may be more sensitivie than RPHA and as sensitivie as RIA.The 
specificity of screening positives was originally confirmed by neutralization with 
human anti-HBs in serially diluted serum samples;the control - sham neutralization 
was performed with human serum devoid of anti-HBs activity.Since this method was la-
boriuos and required relatively large quantities of human anti-HBs,a more efficient 
one-step in situ blocking with human anti-HBs was developed by our group for this 
purpose (Kacaki et al.-20).The publication forms a part of this thesis. 
The merits of EIA for the detection of HBsAg were then tested in a multicentre trial 
(Kacaki et al.-21) in 18 centres in 11 European countries.The publication forms a 
part of the present thesis.On the basis of the results obtained in over 65 000 se-
ra (over 55 000 blood donor sera),EIA was shown significantly more sensitive than 
RPHA.The mean percentage of false positives was 2,2%.Comparison with RIA showed 
a comparable sensitivity. 
A potentially important advantage of EIA over RIA lies in the fact that the enzyme 
label has a much longer shelf life than the radioactive label,and,although its resul-
ts are most accurately read by photometry,they can also be read by the naked eye,as 
done throughout the clinical trial (21),making EIA applicable in circumstances when 
RIA is not possible. 
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What is the practical gain of applying very sensitive techniques for 
the detection of HBsAg in blood donors? 
The answer to this question requires the knowledge of the consequences of transfu­
sion of blood positive for HBsAg before any screening has been done.Gocke reported 
(22) the results of such a prospective study in 84 surviving recipients of blood 
not previously screened for HBsAg.Hepatitis В or circulating HBsAg was found in 44 
(52%) recipients.while an additional 19 (23%) developed anti-HBs,leaving 21 (25%) 
with no evidence of HBV infection.Giorgini et al. (23) have found PTH in 7/161 re­
cipients (4,3%) of blood not screened for HBsAg.When such testing was retrogradely 
performed by ID and CIEP they were able to demonstrate that only 1/7 patients had 
received HBsAg positive blood.A repeated testing by RIA provided evidence that in 
addition,4/7 patients with PTH had received HBsAg positive blood.Zuckerman (24), 
reviewing this problem,estimated that a reduction of PTH by 30% has been acheived 
by the use of pre-RIA methods for detection of HBsAg,and indicated that this re­
duction may be somewhat increased by the use of more sensitive methods.The most spec­
tacular reduction of PTHB by 63% was reported by Goldfield et al.(25).This reduction 
was,however,achieved by a combination of the exclusion of conmercial blood donors 
and the application of RIA for the determination of HBsAg in volunteer blood do­
nors. 
At the present stage it seems that the answer to the question stated above may be 
that the very sensitive techniques for detection of HBsAg,such as RIA and EIA,may 
be applied by those who can afford paying their high costs.One should realize that 
the effect of these techniques in further reducing PTH - in addition to the effect 
of the ones used now - is rather small.The minimum (and maybe even an optimum?) re­
quirement is the use of RPHA.as stated by WHO (26). 
Anti-HBs 
The risk of the use of anti-HBs positive blood in blood transfusion has been exten­
sively studied.In spite of some results,such as those of Renton and Wadsworth (27), 
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claiming that anti-HBs positive blood is four times as infectious as "normal" blood, 
the general consensus is reached that anti-HBs positive blood does not carry a hi­
gher risk of PTHB.This has been documented by a number of prospective studies;it 
suffices to refer here to one of them. Aach et al.(28) were unable to confirm a hi­
gher risk in 133 recipients of anti-HBs positive blood.The control group consisted 
of 145 recipients of ал^-НВ5 negative blood.Consequently,screening of blood donors 
for anti-HBs with the aim of rejecting the positives has been abandoned.Occasional 
screening of donors for anti-HBs in order of detecting highly positive ones remains 
a practical tool for assuring a continuity in the preparation of human anti-HBs immu­
noglobulin concentrate for specific passive immunization. 
HBcAg 
Since the "naked" HBcAg can not be detected (as far as known) in previously untreated 
blood,no methods for its detection are applicable for blood donor screening. 
Anti-HBc 
This antibody was first described as a part of the HBcAg/anti-HBc antigen-antibody 
system being independent of the HBsAg/anti-HBs system by Almeida et al.(29).This 
antibody does not have a protective effect;it appears early in the course of HBV 
infection,providing thus a sensitive infection marker (30).The methods for its 
determination have gone through the familiar evolution similar to those for HBsAg. 
Currently most sensitive methods available are the indirect irmiunofluorescence and 
the RIA (31). 
The practical interest of anti-HBc for blood transfusion lies in the observation 
of Hoofnagle et al.(30) that in a number of blood donors this may be the only mar­
ker of HBV infection.Hoofnagle et al.(31) proposed a hypothesis according to which 
persisting anti-HBc as the sole marker of HBV infection may be an indicator of a 
continuous replication of HBV»with circulation levels of HBsAg below the level of 
detectability by RIA.They have illustrated this by demonstrating retrospectively 
that the transfusion of such blood may result in PTHB.This was further elaborated 
by the same group (33,34).We were also able to observe a case of PTHB after transfu-
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sion of blood positive for anti-HBc only.In spite of the absence of HBsAg in donor 
screening by RIA,it was possible to demonstrate its presence after an appropriate 
concentration of such sera (35).This paper forms a part of the present thesis. 
There have been suggestions,such as those of Lander et al.(36) that blood donors 
should be screened for anti-HBc.We have compared indirect immunofluorescence and 
RIA for the determination of anti-HBc in blood donors and tested 2000 blood donor 
sera for this HBV marker (37).This resulted in detecting 9/2000 (0,4%) donors po-
sitive solely for anti-HBc.It was felt that,before a prospective follow-up of reci-
pients of such (RIA) anti-HBc positive blood becomes available,elucidating the risk 
of contracting PTHB under such circumstances,such screening of blood donors is pre-
mature.This applies even more so because it would result in the introduction of an 
additional screening test,next to the RIA for HBsAg,increasing thus the logistic 
and financial burden of a blood bank.The last word concerning this question is not 
said yet,awaiting further results.This paper forms a part of the thesis. 
HBeAg/anti-HBe 
This antigen/antibody system was described by Magnius and Epsmark in 1972 (38).The 
nature of this antigen,i.e. whether it is a part of a virus particle,coded by virus 
or synthetized by the host in response to HBV infection is not clear yet.Our contri-
bution to the ongoing controversy is a preliminary impression based on ID determina-
tion of HBeAg.that the latter possibility may be the truth (39). 
Since HBeAg has never,to my knowledge,been observed as a sole marker of HBV infection, 
screening of blood donors for HBsAg would always identify those positive for HBeAg. 
Its practical importance lies in the fact that it appears to be an indicator of high 
infectivity of such blood (40). 
The techniques for determination of the presence of these HBV markers went again 
through the same sequence of development from ID to RIA and EIA (41).With this latter 
technique we have found an indication that anti-HBe may be the only marker of HCV in-
fection in some blood donors (42).This finding needs confirmation and its practical im-
plications for blood transfusion are not clear yet,but,in final consequence,this may 
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place anti-НВе into a similar position as that of anti-HBc.This paper forms a part 
of the present thesis. 
Conclusion 
All the efforts throughout the last ten years towards the detection of HBV markers in 
blood donors have contributed to a marked decrease of post-transfusion hepatitis (24, 
25).Further work on improving the sensitivity and the scope of the detection of HBV 
markers may be expected to bring only little improvement in comparison with the re­
sults reached by now.This brings us to the point when one is able to visualize that 
although the incidence of post-transfusion hepatitis В has decreased,there will re­
main a considerable proportion of PTH showing no markers of HBV infection and called 
by Prince et al. "non-B/non-A" hepatitis (43).The proportion will vary from country 
to country. 
While we were fotunate enough by now to have dealt with HBV,a virus with a defect 
in assembly of infectious virions (44),giving rise to high quantities of easily detec­
table virus products in cells and blood circulation,the question remains whether the 
agent(s) of "non-B/non-A" hepatitis will be so "generous".This,however,represents 
a challenge for the ongoing and future research. 
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Results of a Multicentre Clinical Trial of the Solid-Phase 
Enzyme Immunoassay for Hepatitis В Surface Antigen 
J. Kataki, G. Wolters, L. Kuijpers and S. Stulemeyer1 
Oiganon ScienufiL Development Group, Oss 
Abstract. The results obtained in a multicentre clinical trial of an enzyme immunoassay 
(FIA) method for hepatitis В surface antigen (HB.sAg) (65,451 sera tested) have demonstrated 
that (his new lest has a significantly higher sensitivity than a reversed haemagglutination test 
(rHA). In a part of the trial, EIA was also compared with radioimmunoassay (RIA). Only a 
small number of discrepant results was obtained with these two tests, indicating similar 
sensitivities. No definite conclusion about a difference in sensitivities could be drawn from these 
results. Although the specificity of the EIA screening test is lower than that of rHA and RIA, 
the mean percentage of false positives was 2.2% of the total number of donor samples screened. 
Presumptive positives in EIA were subjected to a confirmatory test based on neutralization 
with human antibodies to HBsAg. After elimination of false positives in EIA screening, there 
was excellent igreement between EIA and RIA results. 
Introduction 
Methods used for screening for hepatitis 
В surface antigen (HB.Ag) in human blood 
or blood products should be at least as sen­
sitive as reversed passive haemagglutination 
(rHA) [World Health Organization, 1977]. 
1 he solid-phase enzyme immunoassay meth­
od (ΕΙΛ) for HB^Ag screening has been 
lound, in picliminary experiments in our 
laboralone., to possess a sensitivity and 
specilicitv similai to that ot the commer-
1
 I ho j u t l i o i s ttibh lo ihaiik Mi / К С loesc a n J 
Mi / /in. Λ . Ι ι -hi-ii .• і . с ікчі i c h i i K . i l lu I,. 
cially available solid-phase radioimmuno­
assay (RIA) for HB,Ag (Ausria II®). This 
conclusion was based on the results ob­
tained in testing four national reference 
panels (Panels 2 and 3 of the Bureau of 
Biologies - BOB - of the USA, the 1st Pan­
el of the National Reference Centre for 
Virus Hepatitis in the Federal Republic of 
Germany, the panel of the Central Labora­
tory of the Blood Transfusion Service of the 
Nethei lands Red Cross). A lollovv-up study 
of 14 patienls with acute viral hepatitis В 
indicated that the senskivitv of F-IA was 
similar to that ot RIA. I IA may have a 
sIHuls lovei ммічіг.іц than RIA toi sub-
lype ad (predominanl in North western Eu­
rope). whereas its sensitivity for subtype ay 
(predominant in some countries in Southern 
and hastern Furope) may be slightly higher 
than that of RIA [Wolten et al, 1976] 
EIA does not possess some of the disadvan­
tages of RIA such as the need for expensive 
counting equipment, a short shelf-life of the 
radiolabelled reagent, and problems con­
cerning the disposal of the radioactive waste. 
The results of the ЫА method can be read 
by the naked eye, thus reducing the total 
cost and time of the test performance A 
more objective reading is also possible by 
measurement in a photometer. After the 
above-mentioned study, we planned and or­
ganized a multicentre clinical trial-' to ob­
tain further data on our EIA test for the 
detection of HB.Ag. This paper gives a 
survey of the results obtained in this multi­
centre trial 
- Punii ipiilini; atuie\ W Gerluli, Ü Stiinini, 
R IItomweir Hygiene Institut der Univeisil.it 
kreuzhcipring S7 M Gutlingcn (I KG) S Soi//. 
J Kulmer, Blutspendedienst des Deutschen Roten 
к reu/es, Sandhofsirasse I, 6 Frankfurt/Main 71 
(FRGl J Ьоиііч. I) Benumon, ( enlre National 
de Iransfusion Sanguine. Hablissement С abanel 
(siege social), d rue Alexandre ( abanel 7S7'>9 
Paris Cedex IS (Ггапсс), A Gii>iisit>;is, S НШІТІ-
Miiuiis Hippokialion General Hospital University 
of Athens Medical School, Dept of Intel nal 
Medicine, Athens (Greece). G Bugiiirdim G Gas-
pon, laboialorio С cntializato. Ospedale Santa 
Orsola, Bologna (llaly), С Ati\, H W Rcesink, 
Centraal laboratoi ium van de Bloedtransfusie-
dienst, Postbus 9190, Amsterdam (The Nethei-
lands), R von den Akker, А С Hekker, Rijks In 
stiluut voor de Volksgezondheid, Antonie van 
I eeuwenhocklaan 9, Bilthoven (The Netherlands), 
Ζ GloskoHska, К Madiilinski, National Instilutc 
of Hygiene, Dept of Immunopathology, Ut Cho-
cimska 24, e о 791 Warsaw (Poland), J M Hei-
mtndez Sanihez, A Julio Ciudad Sanitaria de la 
Segundad Social, Servicio de Henialologia ρ о 
Materials and Methods 
Mtlhoth fin HBAg Delation 
bolid-Pliase I ti;\me Immunoassii\ 
The screening lest was performed as described 
by Wollen et al |1976|, using the naked-eye 
reading method I h ree observéis read the lesult 
(·- οι -) independently of each other. The majority 
was taken as decisive Picsumplive positive results 
wire confirmed as described by Knioki et ui 
119771, using the blocking of HB Ag bound to 
the so.id-phase by unlabclled human antibodies 
to H B A g (anti HB ) As a pari of the specific­
ity control, a sham neulralizalion wiih normal 
human seium was perfoimed as well as a lepeat 
screening test The fust screening result was con 
sidered false positive if the reaction in the con 
fnmatoiy tesi was not inhibited by anli-HB , οι 
if the repeal scicemng icsiill was negative 
Re\eise Possm Ничпиціііиітшіоп 
Hepanosiicon" icagcnl (Organon Tekmka 
Oss, The Nelhei lands) was used as descnbcd by 
Sduiiirs and Kamki [1974] Absorption with 
Valle Hebion S N Barcelona 16 (Spam), R Hut 
lei I Builei, /emiallaboratoniim Blutspende 
diensl SRk Wankdoifslrasse 10, 3000 Bern 22 
(Switzeiland) J Jenkins, h Wheeler, National 
Blood Tiansfusion Service, North Fasi Thames, 
Regional Iransfusion Centie, Crescent Drive, 
Bientwood Fssex. S M I S 8 D P ( U k ) , A Barr, J 
Walhue, Glasgow and West of Scotland Blood 
liansfusion Service, law Hospital, Carluke, Ian-
arks (Scotland), Л 7iu keinian, A Zanetti, Lon 
don School of Hygiene and Tropical Medicine, 
keppcl Slreet, London WC 1Г7НТ ( U k ) , В Co­
hen, Ь Vande\elde, Virus Reference Laboratory, 
Central Public Health laboratory, Colindale Ave­
nue, London NW9 SHT ( U k ) . V A Burle\, I V 
Golosina, Central Institute of Hacmatology and 
Blood Transfusion, Novozijkovskii Proezd 4, Mos­
cow 167 (USSR), ß MaksimoMí, h. Slam и, Insli-
tule of Blood Transfusion of Serbia, Svetog Save 
19, Belgrade (Yugoslavia), M Budnnir, S Crnie\ic, 
Institute of Rheumatism, General Zdanova 69, 
11000 Belgrade (Yugoslavia), У Mudru, В Vuko-
w<, Infektivna kl imka Medicinskog Fakulteta, 
Hajduk-Veljkova I, Novi-Sad (Yugoslavia) 
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Hepanosticon absorbcnl was performed according 
to the instructions of the manufacturer to confirm 
presumptive positives 
Solid Phase Radioimmunoassay 
Ausna II was performed as prescribed by the 
manufacturer (Abbott Laboratories, North Chica­
go, 111 ), except for .one centre which used its own 
RIA method (CNTS, Pans) having the same sen­
sitivity as Ausna II [Bcnamon, personal commun , 
1976] Another centre (Gottingen) used micro-
titration plates coated with human anti-HB4 as 
a solid phase and Ausna II issi-labellcd anti­
bodies, giving the same sensitivity [Cerhch and 
Thomssen, 1975] Whenever feasible, presump­
tively positive results were confirmed by neutral­
ization of the antigen with human anti-HB 
according to the manufacturer's instructions 
Organization of the Mullitcntre Trial 
AH sera (or plasmas) were to be screened 
simultaneously in the EIA and rHA by the partic­
ipating laboratories One centre did not perform 
rHA on donor sera All samples giving discrepant 
results were to be subjected to another sensitive 
and specific test for H B A g which would enable 
us to judge the correctness of the results in one or 
the other test 
Since the only other technique with high sen­
sitivity available at the time the trial began was 
RIA, it was accepted that this test would be per­
formed on all discrepant samples It was to be 
performed locally in the participating centre if 
routinely available If this was not the case, the 
discrepant samples were to be sent to our labo­
ratory for RIA RIA screening is highly specific 
(see also 'Results) For this reason, and because 
confirmed RIA results were not received for all 
RIA positives, we accepted RIA screening results 
as a criterion for a final conclusion about samples 
giving discrepant results with rHA and EIA The 
centres routinely using RIA were asked to test as 
many samples as possible with this methods as well 
Because of considerable differences between 
frequencies of HB Ag among blood donors in 
different countries, we distinguish two mam geo­
graphic regions of Europe, namely Northwestern 
Furope covering the participating centres in Great 
Britain, France, The Netherlands, Switzerland and 
the Federal Republic of Germany and Southern 
and Eastern Europe, covering the participating 
centres in Spain, Italy, Yugoslavia, Poland, Greece 
and the USSR 
This trial was performed in two distinct phases 
panel phase and donor phase 
In the panel phase, the participating centres 
were asked to test a number of sera from their 
collections for which the results of HB Ag test­
ing by several techniques were already known 
A number of these sera originated either from 
the follow-up of patients with acute viral hepatitis 
B, or from the epidemiological study in a home 
for menially retarded children, or from the daily 
routine work of the participating national refer­
ence centres 
In the donor phase, sera or plasmas from 
blood donors were tested 
Statistical Analy sis 
The binomial test was used to compare results 
obtained with FIA and rHA It should be noted 
that only sera with discrepant results between 
EIA and rHA were used for the analysis Separate 
binomial tests were carried out for RIA-positive 
sera and for RIA-negative sera 
Results 
General 
The total number of samples tested with 
EIA was 65,451, ι e. 9,756 in the panel 
phase and 55,695 in the donor phase The 
numbers of donor sera and plasmas tested in 
the different European centres and the prev­
alences of HB4Ag found by EIA among 
these blood donors are given in figure 1. 
The number of samples tested with both 
EIA and rHA was 8,497 in the panel phase 
and 54,474 in the donor phase 
EIA results are summarized in table I, 
which gives a survey of the percentages of 
screening positives, specific positives and 
false positives (conclusion based on EIA 
specificity control) As shown in table II, 
false-positive results were subdivided into 
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36 
15%) 
MOSCOW 
5019 
(£6%) 
BARCELONA 
5,000 (1.8%) 
GOTTINGEN 
Αΐ204 
(0.3%) 
A 
FRANKFURT 
7080 (0.3%) 
BELGRADE 
4,982 
(4.8%) 
Fig. 1. Numbers of blood donors tested for 
HB Ag by EIA in 11 European centres. The 
percentages ¡n brackets give the prevalence of 
HB Ag as found by EIA after confirmation. 
Centres in Northwestern Europe are represented 
by triangles and centres in Southern and Eastern 
Europe by circles. 
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Table Ι . Γ Ι Α results 
Regions o f 
Europe 
N o r t h west 
South and Fast 
Total 
Panel 
screening 
positives1 
1,794 \ 5 8 6 
0 2 1) 
1,724'4,170 
(41 1) 
1,518 9,756 
(16 1) 
c o n f i r m a t i o n 2 
specific+ 
1,469/1,794 
(819) 
1,212 1,724 
(70 3) 
2,681 1,518 
(76 2) 
false+ э 
115 1,794 
(7 5) 
221 1,724 
( 1 2 9 
158 1 518 
(102) 
Donor 
screening 
positives' 
968 31,694 
(2 9) 
1.016 22 001 
(4 7) 
2,004 55,695 
( 1 6 ) 
conf irmat ion 2 
specific + 
58 968 
(6 0) 
691 1,016 
(66 7) 
749 2,004 
(37 4) 
false + 3 
901 968 
(93 1) 
317 1,016 
(10 6) 
l,220'2,004 
(60 9 ) 4 
1
 Percentage of the total number screened is given in paienthcscs 
2
 Specific and false positives (after the s p c u l i u i y control) Percentage in reference to screening positives given 
in parentheses Not mentioned in this table prcsumpmc positives not available for specificity control or giving 
inconclusive results 
1
 Negative in repeated screening or nonspecific reaction (after the spccihcitv control) 
4
 This corresponds to 2 2 % of the total number screened 
Table I I . f u r t h e r analysis of the false positives in [ Ι Л 
Region of H i r o p e Total number of false 
positives in screening 
panel donor 
I aise positives being negative 
m repeat screening' 
panel donor 
North west 
South and L ast 
Total 
115 
221 
158 
901 
117 
1,220 
108 
HO 
218 
80 0 
58 1 
66 4 
895 
176 
071 
1
 The remainder were nonspecific positives, 1 e repeatedly positive and not ncutralizable by anti-HHs 
99 I 
55 5 
87 8 
'repeat negatives ' and nonspecific samples 
It is interesting that at least 5(lÇ? of the lalse-
posittve results in EIA screening belong to 
the group of repeat negative cases 
The total number of discrepancies be-
tween three readers was low (1 89f in the 
panel phase and 0 7% in the donor phase). 
1
 Samples found negative upon icpelmon of the 
screening pioccdt i rc per fo imed as a part of the 
speuf iu lv cont ro l 
С ompansun of EIA and rHA, Using 
RIA as a Criterion 
As mentioned under "Methods', RIA 
screening is highly sensitive but also highly 
specific Only 1 57c of the samples positive 
in RIA screening became negative after 
conlirmation (17/482 and SX'ILOS m the 
donor phase and the panel phase, respec­
tively) Moreover, the specificity control in 
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Table I I I . Comparison of EIA and r H A 
Ι IA Positive1 
гНА + rHA 
Negative1 
гНА + r H A -
4 Panel phase ( 17 centres) 
Screening 
+ 
After spcuhcit) c o n t r o l 2 
f 
2,157 
IH 
1,785 
12 
384 
80 
357 
114 
19 
282 
4 
28 
383 
5,154 
54 
5,706 
В Donar phase in Noilhweslein Europe (5 centres) 
Screening 
+ 47 
/ 
After specificity control -
+ 46 
/ 
21 
ή/5 
877 
10,924 
3 
32,404 
С Donor phase in Southern ami Eastern Europe (5 centres) 
Screening 
4 452 228 
6 7 
After speulicity c o n t r o l J 
+ 444 
/ 
224 
23 
10 
147 
329 
20,805 
12 
21,253 
1
 Criterion RIA screening result found either by participating centre or by us, if no R I A result was available 
and the results with [ I IA and r H A after confirmation were identical, the latter were considered correct. 
1
 Samples not avaible for confirmation in either F IA or r H A and sample giving inconclusive results in E IA 
continuation, are not included in this part of the table 
R I A was noi ¡ilways performed by the par-
t ic ipadng Lcnlres. Therefore, the outcome 
of R I A screening was used as a cr i ter ion for 
the comparison ol E I A and r H A , both in 
screening and afler specificity contro l I f 
R I A results were not available, the L I A and 
r H A results after conf i rmat ion were con-
siderect conect if they were identical The 
comparative results of F I A and r H \ are 
pie-.enled in table I I I A - C 
In the panel phase, a higher number of 
positives (as judged by R I A ) was found wi th 
F I A than wi th r H A (both in screening and 
alter specificity contro l ) . For example, it 
can be seen in table M I A that after conf i r -
mat ion, 357 positives were only detected by 
E I A versus 12 specific positives only de-
tected by r H A and not by E I A ' Ihe dif fer-
ence was statistically sigmhcant (p < 0 05) 
lo i most ol the part ic ipat ing centies This 
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demonstrates that EIA is more sensitive 
than rHA With respect to negatives (as 
judged by RIA), seven centres had signifi-
cantly (p < 0 05) more positive reactions 
with EIA screening than with rHA screen-
ing, whereas three centres had the reverse 
These data indicate that the specificity of 
EIA screening is lower than that of rHA 
screening 
In the donor phase, in Northwestern Eu-
rope, no statistically significant dilïerence 
was found between FIA and rHA (both in 
screening and after specificity control) with 
regprd to RIA-positive samples (table ШВ) 
However, there was a significant difference 
(p < 0 01) in this respect for all five centres 
in Southern and Eastern Europe the num­
ber of specific positives with EIA, not de­
tected by rHA was 224 versus 1 EIA-/ 
rHA+ (table UIC) Thus, EIA appears to 
be significantly more sensitive than rHA in 
Southern and Eastern Europe 
The difference between the numbers of 
( incorrect') positives with EIA and rHA 
found after screening the group of RIA-
negatne samples was significant in most of 
the ten centres Three centres in North­
western Europe and four centres in South­
ern and Eastern Europe found more posi­
tives with LIA One Northwest-European 
centre found more positives with rHA This 
indicates that rHA screening has a higher 
specificity This difference was eliminated 
after specificity control Two centres even 
found significantly (p < 0 05) more posi­
tives with rHA than with EIA 
Comparison of CIA and RIA 
The results of screening and confirma­
tion with EIA and RIA in the panel phase 
Tabic IV. Comparison of EIA and RIA, both 
screening and after specificity control 
Screening 
hIA RIA 
I 
A Panel phase 2 
1,249 131 
103 2,784 
В Donor phase ' 
144 614 
11 26,457 
АГіег 
ЫА 
9 4 
9-1 
specificity control 1 
RIA 
728 
5 J 3 
3 
136 
9 
0 
25 
2 884 
15 
II 
26,941 
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1
 This table contains only data on samples that 
were tested for specificity in both EIA and RIA 
Results from 8 centres where RIA was done 
routinely 
' When 9 out of 24 samples from one centre were 
tested in RIA by us, they were all negative The 
remaining 15 were not available 
4
 Inconclusive results in the specificity control for 
EIA True positivily could not be confirmed with 
absolute certainty 
' Results from 5 centres where RIA was done 
routinely 
are given in table IVA These data come 
from eight centres where RIA was per­
formed routinely. 
The corresponding data for the donor 
phase, obtained in five centres are given in 
table IVB (note that the confirmation was 
not performed in all cases) The specificity 
control does not always give a clear-cut and 
correct result for either EIA or RIA This 
can be illustrated as follows samples that 
were still available and had given discrepant 
lesults (as between EIA and RIA) after 
specificity control performed by the inves­
tigators were retcsted in the Organon labo­
ratory If specific positivity in EIA and'or 
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Table V. Further test results on samples giving discrepant results after confirmation m EIA and RIA 
Results in centres Results after relesting1 (Organon) 
after confirmation 
panel donor 
'lrue'+ negative NA 'true'+ negative NA 
EIA-/RIA+ 23 IO2 20 7 0 2 
ΕΙΑ + , Κ Ι Α - 6 3 16 3 2 6 
E [ A ' ' / R I A + 3 0 0 0 0 0 
h l A V R I A - 2 6 7 0 г і 3 I 
NA = Not available 
1
 Specific-positive in either CIA or RIA designated 'truc'H-, negative in both EIA and RIA (ratio -.1 5) 
designated negative 
2
 9 from one centre 
3
 18 from one centre 
RIA was found, the results were called 
'true' positive When retesting was negative 
with both EIA and RIA (ratio < 1 5), the 
final conclusion was 'negative' These re­
sults are given in table V 
Discussion 
Sensitivity and specificity are important 
aspects of any screening test for HB^Ag 
The sensitivity of the EIA test was 
studied in relation to two other current 
test systems, rHA and RIA EIA had, in a 
number of participating centres both in the 
panel and the donor phase, significantly 
higher sensitivity than rHA (table IIIA, C) 
This holds true both for screening and after 
specificity control Although statistical meth­
ods were applied to compare EIA and rHA 
results in panels, these results should be 
interpreted cautiously because panels are 
not representative for the donor population 
to which the test will be applied in practice 
In the donor phase, significant differences 
were obtained only in the South- and East-
European participating centres. This is not 
surprising, since the prevalence of HB^Ag 
in the Northwest-European population is 
much lower than in the population of South­
ern and Eastern Europe (fig 1), thus ham­
pering an easy demonstration of differences 
in sensitivity between the two tests in North­
western Europe (for this, a much greater 
number of sera would be needed) With 
regard to the comparison of the sensitivities 
of EIA and RIA, the results obtained in the 
panel phase (table IVA) differ from those 
in the donor phase (table IVB) In the panel 
phase, the number of specific positives with 
RIA missed by EIA is greater than the num­
ber of specific positives with EIA missed 
by RIA (53 vs 25) 
The results of one centre greatly influ­
enced the outcome The number of 53 EIA-/ 
RIAt in table IVA (after specificity control) 
consisted for almost 50% of samples from 
this centre When 9 of these 24 samples 
were tested in the Organon laboratory with 
RIA (15 samples were not received), they 
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were all negative. This irulicates that these 
samples may give at least questionable re­
sults with RIA. 
On the other hand, the 25 EIAt/RIA-
(after specificity control) also consisted of 
some questionable positives (table V). In 
the donor phase (table IVB), one can see 
that of 27,119 samples tested simultaneously 
by EIA and RIA (specificity control in­
cluded), 9 cases were found to be positive 
with RIA and negative with EIA. whereas 
11 specific positives with EIA were missed 
by RIA. 
A statistical analysis of these results 
would only be justified if a reliable criterion 
for the presence of HB,Ag were available. 
If the specificity control of the respective 
tests is considered a reliable criterion -
which is disputable - no significant differ­
ence (11 vs. 9) between EIA and RIA with 
respect to sensitivity can be demonstrated 
in this study of donor blood samples. 
The specificity of EIA in comparison 
with that of rllA in the panel phase without 
confirmation test was significantly lower in 
a number of centres. This is reflected by the 
higher number of presumptive positives with 
EIA in the group of samples considered 
negative by RIA (table IIIA). However, af­
ter specificity control, this difference dimin­
ished greatly. The remaining differences 
may be partly explained by a relatively 
lower sensitivity of RIA towards subtype 
ay. As previously described [Wolters et al., 
1976], EIA may have a slightly higher sen­
sitivity than RIA for this subtype. 
In the donor phase, the EIA screening 
test was also less specific than the rHA 
screening test in a number of centres, but 
after specificity control, this difference com­
pletely disappeared. The present study shows 
a lower specificity of EIA screening in com­
parison with that of RIA on the basis of the 
results of the respective confirmatory tests. 
In RIA, 3.5% of the presumptive positives 
could not be confirmed as specific. The 
corresponding percentages for EIA were 
10.2 and 60.9% in the panel and donor 
phase, respectively (table 1). 
From a further analysis of the number 
of false positives in the EIA screening, it 
becomes evident that, in the donor phase, 
99.1% of false-positive samples from the 
Northwest-European centres were, in fact, 
samples negative in the repeat test which is 
an integral part of the confirmation proce­
dure (table II). In other words, in these 
cases it would have been sufficient in the 
first instance to repeat the screening proce­
dure without performing the full specificity 
control. The reason for these 'repeat nega­
tive" results is not yet fully clear. 
There seems to be a correlation with the 
freshness of the sera tested; however, we 
could not confirm this in about 700 fresh 
donor sera [Wolters et ai, 1976]. In some 
centres, preheating of fresh sera at 56 С 
for 30 min, or ageing for 1-2 days in a re­
frigerator, diminished greatly the number 
of such cases [Butler and Butler, personal 
commun.]. The favourable effect of heating 
at 56 С could not be confirmed in our 
hands. During the course of this multicentre 
trial, a clear-cut diminution of false-positive 
results was noted. This may have been 
caused by the increase in technical expe­
rience in performing the test, especially in 
the washing procedure [Maksimovic, per­
sonal commun.; Wallace and Barr, personal 
commun.], which is extremely critical. Our 
experience is that if the plates are carefully 
washed after the second incubation step, 
the number of non-repeatable positives in 
EIA and RIA are of the same order. 
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In South- and East-European centres, 
the proportion of repeatable ('true') false 
positives was much higher than in North-
west-European centres. This may indicate 
that nonspecifically reacting factor(s) occur 
more frequently in Southern and Eastern 
Europe. However, the false positives repre-
sented only 0.6% of the total number of 
donor samples screened in that area. In 
none of the Northwest-European centres, 
where the incidence of HB.Ag-positive 
blood donors is low, did the number of 
EIA-screening-positive samples, i.e. specific 
and false positives taken together exceed 
5.5% of all the donors tested. The mean in 
this area was 2.9%. The percentage of false 
positives of all donor blood tested in this 
study was 2.2% (table I). From the data in 
table IVB it can be calculated that the num-
ber of 'incorrect' specific positives must be 
less than 0.04% (i.e. if all 11 EIA+/RÏA-
were negative for HB4Ag). Therefore, we 
conclude that application of the neutraliza-
tion procedure as a specificity control of 
presumptive positive samples will not pres-
ent a practical problem and will give re-
liable final results. 
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Specificity control in solid-phase 
enzyme immunoassay for HBsAg 
by one-step in situ blocking with 
human anti-HBs 
J KACAKI1, G WOLTERS, L KUIJPERS, AND A SCHUURS 
Organon Scientific Development Croup, Oss, The 
Netherlands 
The solid-phase enzyme immunoassay (EIA) for 
HBsAg2, described by Wolters et al (1976), has a 
similar sensitivity as a commercially available 
sandwich-type solid-phase radioimmunoassay (RIA) 
In the same paper, a method for the confirmation 
of presumptive positives was described As this 
method is laborious, we have attempted to develop 
a simpler one, which is based on the in situ blocking 
of the antigen bound to the solid-phase antibody by 
human antibodies against HBsAg (anti-HBs) Essen-
tially the same principle has also been reported for 
the specificity control of presumptive positives in 
RIA (Lmg et al, 1975) 
Human anti-HBs is often preferred as neutralising 
antibody because the risk of neutralising non-
specifically reacting factors is small However, one 
must be sure that HBsAg of one subtype, for 
example, ay, will be neutralised by antibodies against 
the other subspccificity (ad)oT by antibodies directed 
only against the main antigenic determinant a 
We describe the results obtained with two different 
human anti-HB, sera comparing the two different 
specificity control methods mentioned above 
Material and methods 
Two human anti-HB, sera were used in this study 
One had the subspecihcity of anti-a> as demonstrated 
by immunodiffusion The subspccificity of the other 
anti-HBs serum could not be determined by this 
technique Both antisera were further characterised 
by determining the highest dilution that still reduced 
the reaction of HBsAg of either subtype in EIA 
It was found, for the anti-oy serum, that the ratio 
'Present address Gemeente Ziekenhuis, Streeklaborator-
lum voor Bacteriologie, Wagnerlaan 55, Arnhem, 
The Netherlands 
'Trade name 'Hepanostika', Organon Teknika Interna-
tional, Oss, The Netherlands 
anii-ad titre anti-ay titre was 1 2 5 For the other 
anti-HBs serum this ratio was 2 1 1 We consider 
this indicates that the latter antiserum contains anti-
bodies to the rf-determinant For the sake of clarity, 
we shall designate this antiserum as 'anti-ad' in the 
following text Both antisera were compared at the 
same strength of anti-HBs, that is, diluted on the 
basis of the 'average' titre 
vXanti-aí/ titre) χ (anti-ay titre) 
The first EIA confirmation method (hereafter 
referred to as 'dilution method') was performed as 
described by Wolters et al (1976) with some minor 
changes A presumptive positive sample was serially 
diluted and incubated for 16 hours at room tempera­
ture in glass tubes with human anti-HBs of either 
subspccificity (Table 1, anti-HBs columns I (ay 
and ad)) 
A sham neutralisation was performed with normal 
human serum (NHS) 1 10 (free from HBsAg and 
anti-HBs) on an identical dilution series of the same 
sample (Table 1, columns II) After the neutralisa­
tion procedure, each dilution was tested according 
to the screening procedure in the anti-HBs-coated 
microtitre wells (Wolters et al, 1976) 
Untreated (undiluted) samples were retested 
simultaneously in order to check the results of the 
screening (Table 1, columns III) If read with the 
naked eye, a titre reduction of at least two dilution 
steps after anti-HBs tieatment, as compared with 
the control treatment, was considered specifically 
positive Objective reading was done by measuring 
extinction at 492 nm (E442) Solutions with E492 > 2 
were diluted 10 χ in 1 34 Ν sulphuric acid and mea­
sured again The percentage of neutralisation by 
anti-HBs was calculated as follows 
% neutralisation = 
(F492H) - (E492I) 
(Ε492Π) - (E49:neg control) χ 100% , 
where 
E4921 = extinction after treating the sample with 
anti-HBs 
E492 II = extinction after treating the sample with 
NHS 
Ei92 neg control average extinction of at least five 
negative control sera tested ac­
cording to the noi mal screening 
procedure 
The performance of the m situ blocking with 
human anti-HBs (hereafter referred to as 'blocking 
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Table 1 Comparison of'dilution' and 'blocking' methods for specificity control in dilution series of sera containing HB,Ag 
of the ay and ad subtypes 
HB.Ag 
(μϊ/m/) 
'Dilution' method 'Blocking' method 
% Neutralisation, Eye reading 
colorimetrie reading 
% Neutralisation, Eye reading 
colorimetrie reading 
Anli-HB, Anli-HB, Anli-HB, Anti-HB, 
I 
ad ay 
III I 
ad 
I 
ay 
III 
ay subtype 
99 4 u 
49-7 · 
24-8 · 
12 4 · 
6-2 · 
3 1 · 
1-5 · 
0-8 · 
0-4 · 
0 2 · 
0 0 9 » 
ad subtype 
13-7 u 
6-8 · 
3-4 · 
1-7 · 
0-9 · 
0 4 · 
0-2 · 
0 1 · 
0 05 · 
0 03 · 
0 01 * 
0 
0 
0 
0 
0 
0 
0 
6 
22 
21 
87 
0 
0 
14 
0 
5 
20 
54 
94 
101 
104 
99 
87 
70 
71 
73 
70 
66 
69 
70 
74 
86 
95 
93 
96 
98 
99 
98 
98 
99 
100 
100 
100 
103 
91 
87 
89 
90 
87 
86 
86 
86 
87 
96 
99 
89 
93 
94 
96 
96 
97 
97 
98 
98 
97 
92 
Ш 
ЩШ 
н^н 
:
 undiluted serum 
serum diluted in saline 
serum diluted in saline containing 0 1 % BSA 
ΥΖ/Ζ/ί 
dark yellow-orange 
light yellow 
3 = colourless 
method') was as follows (see Figure): 100 μΐ of test 
sample was added to four different wells of an anti­
body-coated microtitre plate (I ad, I ay, II, and III). 
NHS was included as a negative control and treated 
further in the same manner as the sample in well III. 
The plates were then covered with parafilm and 
incubated for 16-24 hours at room temperature. 
Wells I and II were emptied by aspiration (well III 
and the control wells were left untouched) and washed 
three times. 150/xl (or four drops) of human anti-HB
s 
of either subspecificity were dispensed into corre­
sponding wells labelled I ay and I ad; 150μΙ (or four 
drops) of NHS I : 10 were dispensed into well II. 
The plate was then covered and incubated for two 
hours at 37CC, after which all wells were aspirated 
and washed three times. Thereupon the procedure for 
screening was resumed, as described previously 
(Wolters et ai, 1976). When read by eye, the interpre­
tation of the results was as follows : 
if the colour developed in well I was weaker than 
in wells Π and III, the sample was regarded as 
specific positive; 
if the colour developed in all four wells was 
equally intensive (and weak), the sample was 
regarded as false positive; 
if no colour developed in any of the four wells the 
sample was also regarded as false positive ('repeat 
negative'). All other combinations of colours 
rendered an inconclusive result. When read colori-
metrically, the percentage of neutralisation in well I 
was calculated by the same formula as described 
above. 
The total amount of antibody used per test sample 
was about the same for both methods. 
Both methods were studied with two sera con­
taining HBsAg, one of the ay subtype and the other 
of the ad subtype. Serial dilutions were made in 
0-9% NaCl (or 0-9% NaCI containing 0-1 % bovine 
serum albumin). The concentration of HB
s
Ag was 
determined using the German Reference Panel for 
HBsAg as a standard (Gerlich et ai, 1976) and was 
99-4fxg/ml for ay and 13-7/ig/ml for erf. Each of these 
serum dilutions was neutralised with both human 
anti-ay and anti-arf. 
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I ad I су 
anti HBi coated wells 
incubale 
aspirale and wash 
wells I ond D 
add 150 μΙ 
V V V 
anil HBS anti HBS NHS 
(anil ad) |anti ay) |1 10) 
incubate al 3 7 0 C , 2 hrs 
ш 
V и V и 
add test sample 100 μΙ "Up V p "lc? t / 
at room temperature, 16 24 hrs 
I 
I 
V 
V V U V aspirale and wash all wells 
add coniugate, incubate, wash, add substrate ond incubate 
according to normal screening procedure 
read colours in wells 
О о 
Figure Flou-chart of the 
confirmatory leil(in situ 
blocking). The lower part shows 
schematically the four most 
tommonly OKurrmg results. 
concluaion 
ipecific + 
О О О 
£ ^ non-specific 
( ) negative 
f ) - no colour visible. light yellow :
 darh yellow.orange 
Results 
The results with lespeet to both subtypes ay and ad 
are shown in Table 1. The results of eye reading 
are given schematically next to the results of colori-
metrie reading in order to facilitate the comparison. 
The same dilution series was also made in normal 
human serum as a diluent and tested in the 'blocking' 
method. The results obtained were essentially the 
same (neutralisation > 75 % in all cases). 
Thirty sera found to be presumptively positive 
in EIA screening (all of them with low and inter-
mediate HBsAg contents) were subjected to speci-
ficity control by the in situ blocking method using 
human anti-oi/, and also tested by radioimmuno-
assay (Ausria II), according to the manufacturer's 
instructions (Abbott Laboratories, North Chicago, 
111, USA). The results are given in Table 2. 
Discussion 
The results in Table 1 demonstrate that the 'blocking' 
method is superior to the 'dilution' method. 
By eye reading in the 'dilution' method one would 
be unable to draw a conclusion if the HBsAg 
concentrations were above a certain level (about 
3 /ig/ml). However, eye reading in the 'blocking' 
method did not present any difficulty for drawing 
a conclusion at any of the concentrations tested. 
Colorimetrically determined percentages of neu-
tralisation in the 'dilution' method are also lower 
than those obtained in the 'blocking' method. 
Thus, the highest concentration of ay neutralised 
in the 'dilution' method by at least 50% (neutralised 
with anti-ay) is between 0-2 and 0 4 ¿¿g/ml; for the 
ad subtype it is a concentration of 0-2^g/ml. In the 
'blocking' method (regardless of the antibody 
subspecificity) even the highest concentrations of 
HBsAg tested had a percentage of neutralisation 
in excess of 50% (Table 1). The results of the 'block-
ing' method thus show a higher efficacy of neutralisa-
tion for both subtypes adand ay. A likely explanation 
is that in the 'blocking' method the solid-phase 
anti-HBs, which has a finite and relatively low 
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Table 2 Campai ¡son of the 'blocking' method Jor specificity control of EIA foi HBtAg with Ausria II scieenmg and 
confit ination tests 
Sample \o 
1 
2 
3 
4 
5 
6 
7 
g 
9 
10 
I I 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
LIA 
Sri·. 
Eye 
T 
— 
— 
— 
_ 
_ 
-
-
-
_ 
_ 
— 
-
_ 
-
-
_ 
-
-
-
-
_ 
-
-
_ 
-
entnn 
reailtit^ Eiit iranol 
3-76 
2 22 
2 15 
3 29 
2 89 
3 21 
2 S6 
2 к ' 
2 u? 
2 28 
3 29 
3 96 
2 SI 
1 \-
2-09 
6-77 
4 95 
2 66 
5 61 
5 20 
4 72 
3 20 
-1 84 
2 33 
4 43 
2 69 
2 42 
) 16 
5 21 
S 16 
Confirntatton 
S 
? 
S 
N S 
S 
S 
S 
S 
S 
S 
Ь 
N S 
*> S 
R N 
N S 
N S 
N S 
N S 
N S 
N S 
R N 
N S 
N S 
N S 
R N 
R N 
N S 
N S 
N S 
Ausrta II 
St reening (rano) 
4 93 
1 15 
5 4 ' 
2 3« 
1 56 
5 Г 
I l 92 
1 1 1 4 
5 l< 
7 26 
7 3>i 
Ι 9·. 
2 9 : 
« 42 
i o : 
ι ι.-0 92 
Ι 0« 
Ι ι« 
0 75 
Ι 04 
0 82 
Ι Î 1 
0 8" 
1 20 
Ι 19 
0 99 
0 6» 
Ι 06 
I) 7f, 
Confirmalíon 
S 
S 
S 
S 
S 
s 
s 
s 
s 
s 
— 
s 
s 
Not done 
.. 
t ! · 
• 
» 
. 
1 I I 
t * · 
. 
1 I I 
1 
. 
. 
specific; ' = inconcluMve, NS =• non-specific: RN »• repeat-negative m conñrmation. 
capacity, binds only a fraction of the total quantity 
of HBsAg offered to it in the first incubation. The 
remaining unbound HBsAg is being discarded. The 
added anti-HB, (in relatively higher quantity per 
well than in the 'dilution' method) has, therefore, 
an 'easier' task in neutralising (blocking) the HBsAg 
bound to the solid phase. 
Both 'dilution' and 'blocking' methods gave similar 
results by eye reading only when the concentration 
of HBsAg in the samples was low (below 0-2 μ% 
HBsAg/ml). 
Economy of time and reagent is also important. 
At least 2 x 6 dilutions of the sample and extra 
undiluted sample are needed for the 'dilution' 
method, thus occupying 13 reagent-wells per sample. 
Strong positives might not reach an endpoint so that 
even further dilution and retesting are necessary. 
The 'blocking' method is performed entirely in the 
antibody-coated microtitre plate and the number 
of wells per sample is only three.1 While in both 
'Instead of two separale wells for antibodies with differ­
ent subspecificities, as described here, only one well и 
used in the routine work 
methods about the same quantity of neutralising 
antibody per sample is used, a saving factor of about 
four with regard to the remaining reagents is ob­
tained by the 'blocking' method. 
The data presented in Table 1 show that the anti-ai 
was slightly more effective in neutralising the ay 
subtype than ad and vice versa. However, it is 
evident that both antisera studied here can be used 
equally well for neutralisation of both subtypes in 
the 'blocking' method. 
Most of the specificity control results obtained 
with the 'blocking' method agreed with the RIA 
results (Table 2). Disagreements were encountered 
in four cases (Nos. 2, 4, 5, and 13 in Table 2). There 
is no practical possibility of finding the correct 
answer since at the moment no method superior 
in terms of sensitivity and specificity to both EIA 
and RIA exists. 
For a multicentre clinical trial of the EIA method 
for HBsAg, which has just been completed, we have 
chosen the 'blocking' method for specificuy control. 
The results of this trial will be published separate!}, 
but it is of interest to note here that, out of over 11(X) 
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cases in which presumptive positivity was found in 
screening, the 'blocking' method gave only 27 
inconclusive results. 
We conclude that the 'blocking' method is super­
ior to the 'dilution' method for specificity control 
of the enzyme-immunoassay for HBsAg for the 
following reasons 
the neutralisation procedure is more efficient; 
it is less laborious; 
it has a reagent-saving factor of about four. 
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Solid-phase enzyme-immunoassay for detection of 
hepatitis В surface antigen 
G. WOLTERS, L K U I J P E R S , J ΚΑΒΑΚΙ, AND A. S C H U U R S 
From the Organon Scientific Development Croup, Oss, The Netherlands 
SYNOPSIS The preliminary results of a solid-phase enzyme-immunoassay (EIA) for the detection 
of hepatitis В surface antigen (HB,Ag) are presented This method has been compared with the 
solid-phase radioimmunoassay (RIA) for HBsAg in dilution series of four HBsAg positive sera, 
four national reference panels (The Laboratory Panel of the Central Laboratory of the Blood 
Transfusion Service of the Netherlands Red Cross, USA BOB Reference Panels Nos 2 and 3, 
and the 1st Panel of the National Reference Centre for Virus Hepatitis at the Institute of Hygiene 
of the University of Gottmgcn, West Germany) In addition, the two lest methods were compared 
in a weekly (up to 16 weeks) follow-up of 14 patients with acute viral hepatitis В It was seen that, 
both by reading EIA test results with the naked eye and by colorimetrie reading, the sensitivity and 
specificity of this test method compared very favourably with those of the RIA EIA may have a 
slightly lower sensitivity than RIA for the subtype ad, while its sensitivity for the subtype ay may 
be slightly higher than that of RIA These minor sensitivity differences may be due to the specificity 
profiles of the antisera used 
Since the discovery of the relationships between 
Australia antigen, now called hepatitis В surface 
antigen (HBiAg), and serum hepatitis (type В 
hepatitis) a number of immunochemical techniques 
with different specificity, sensitivity, and practic­
ability for the detection of HBsAg have been des­
cribed A recent survey of these methods is given in 
a WHO Technical Report (World Health Organiza­
tion, 1975) For a number of years our laboratory 
has worked on the development of a new and sen­
sitive immunochemical technique, the enzyme-
immunoassay (EIA) (van Weemen and Schuurs, 
1971, 1972, van Weemen et al, 1974) This method 
has also been studied by several other groups of 
investigators, particularly by Engvall and Perlmann 
(1971, 1972) and Engvall et al (1971) The present 
paper describes the application of a solid-phase 
enzyme-immunoassay for the detection of HBsAg 
Materials and methods 
H E P A T I T I S В S U R F A C F A N T I G E N 
Purified HBsAg was obtained from positive donor 
plasmas in the way described by Schuurs and 
Wolters (1975) 
S H F E P A N T l - H B s , G AMM AG 1 О B U L I N 
Sheep were immunized by repeated intramuscular 
injections of purified HBsAg in complete Freund's 
adjuvant at two-week intervals until a reciprocal 
titre of antibody to HBsAg (anti-HB,) of 3=512 in 
a standard immunodiffusion set-up was attained 
with both subtype ay and ad The resulting anti­
serum was tested by immunodiffusion against normal 
human serum (undiluted and diluted from 1 2 to 
1 32) The antiserum was absorbed with insolubilized 
normal human serum proteins until no antibodies 
to human serum proteins could be detected The 
gammaglobulin fraction was precipitated with 14% 
(w/v) Na2S04, and the precipitate was dissolved in 
0 0175 м phosphate buffer pH 7 6 and dialysed 
against the same buffer 
A N T I B O D Y - C O A T t D M I C R O T 1 T R E P L A I E S 
The wells of Microliter11 plates (Cooke) were 
filled with 0 1 ml sheep anti-HBs gammaglobulin 
fraction having a protein concentration of 0 03 
mg/ml The liquid was removed from the plates 
after overnight incubation at 4 C, the plates were 
washed four times with 0 04 м TRIS-buffer pH 7 4, 
dried over silicagel, and stored at 40C in the presence 
of silicagel 
Λ Ν Τ Ι Β Ο Π Υ - Γ Ν Ζ Υ Μ Ε C O N J U G A T T 
Horse-radish peroxidase (Miles, RZ 3 0) was linked 
to sheep anti-HB gammaglobulin in a protein 
ratio of 4 I by the 'two step' method of Avrameas 
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and Ternynck (1971) using 2 0 0 glutaraldehyde. 
The (anti-HB,)-enzyme conjugate was recovered by 
precipitation with \4"/0 (w/v) NasSOj The conju­
gate was dissolved in a 0-2 м TRIS-buiïer of pH 7 4 
and used in a concentration designed to give an 
average extinction of about 0-100 in the test of the 
negative control (see below). 
С H R O M O G t M C C O M P O U N D FOR T H f E V Z V M E 
REACT ION 
Ortho-phenylene diamine was regarded as the most 
suitable chromogen in spite of its light-sensitivity. 
In comparison with a number of other compounds 
examined it had the following advantages 
(a) the most sensitive test results were obtained, 
(b) the colour development was edsil> stopped; 
(c) the coloured reaction product was stable for 
man) hours and did not precipitate, not even 
at high concentrations 
HI MAN AN Τ Ι-Η В s 
Human anti-HBs used for confirmation of pre­
sumptive positive sera was obtained from the Central 
Laboratory of the Blood Transfusion Service of the 
Netherlands Red Cross (CI B) On the basis of 
a test as described under 'Detection ol anti-HBs' 
(see below), the reagent was used in a dilution of 
I 10 It could completely neutralize positive reac­
tions of test samples giving extinctions of 1-9 or 
lower in the screening test 
N O R M A ! H l . M A N S E R U M 
Pools of at least five normal human sera were used 
for negative controls and for sham neutralization 
in the confirmatoo test They were selected on the 
basis of the absence of HIKAg in radioimmunoassay 
(RIA) and Ы А and ofanti-HBs in EIA 
O R I G I N Ol T h S I S A M P L I S 
The I aboratory panel of the Central I aboratory of 
the Blood Transfusion Service of the Netherlands 
Red Cross (CI В panel) was kindly made available 
to us by Dr. H Reesink BOB Reference panels 
Nos 2 and 3 were kindly supplied by the United 
States Department of Health. Idueation and 
Welfare, Public Health Service, Bureau of Biologies, 
Food and Drug Administration The 1st Panel of 
the National Reference Centre for Virus Hepatitis 
at the Institute of Hygiene of the University of 
Gottingen, West Germany was obtained by coui lesy 
of Professor R Thomssen 
Serial serum samples of hospitalized patients 
withacute viral hepatitis type В were collected weekly 
for up to 16 weeks after the initial symptoms and 
kindly made available by Professor V. Mudnc, 
School of Medicine, University of Novi Sad, 
Yugoslavia1 Fresh donor sera (not older than 36 
hours) were kindly supplied by the CI.B (Dr H. 
Reesink) 
P F R E O R M A N C E Oh T H E S C R E E N I N G T E S T 
A 0-1 ml test sample (or a positive or negative 
control) was pipetted into an (anti-HBsJ-coated 
well of a Microliter" plate and incubated for 
2 hours at 37 47 The wells were aspirated and washed 
three times with 0-2 м TRIS-buffer pH 7-4. 
0 1 ml of the antibody-conjugate solution was 
then added to each well, incubated for 2 hours at 
37 C, and removed by aspiration The wells were 
afterwards washed four times with the same TRIS-
bufler. 
0 1 ml of a freshly prepared solution of o-pheny-
lene diamine (0-4 mg/ml) and urea peroxide 
(0-2 mg ml) in a phosphate-citrate buffer of pH 5 0 
was added to each well and incubated in the dark 
for 50 minutes at room temperature. The en/yme 
reaction was stopped by adding 005 ml 4 N sul­
phuric acid 
The yellow colour of the product of the en/yme 
reaction was read by eye against a diffuse white 
light source placed underneath the Microliter" 
plate and/or by measurement of the extinction at 
492 nm m a mierocuvetle of a Vitatron colori­
meter. 
If read by eye, a sample was called positive when 
its colour was stronger than that of the negative 
control (Usually, extinction values below 0-200 
could not be distinguished by eye from those of the 
negative control having an extinction of about 
0-100 ) When measuring extinction, the ratio. 
Elest sample — Lhlank ΙΓ 
Elilank I — Eblank II 
was considered to represent a positive reaction 
Ebianh ι was the average extinction of hve negative 
serum controls, bmank u the extinction of 0-1 ml of 
a solution containing o-phenylene diamine and 
urea peroxide as described above, mixed with 0-05 ml 
4 Ν sulphuric acid. 
A ratio of less than 2 1 and more than 1-5 was 
considered to be equivocal ( ± ) 
C O N F I R M A T I O N OF P R E S U M P T I V E P O S I T I V E S 
Samples found positive in the screening test described 
above were serially diluted in 0-9% NaCI (undiluted 
to 1 32 with a dilution factor of 2) and subjected to 
a neutralization procedure- 100 μΐ of each dilution 
'The clinical details, as well JS the correlation of the enzyme 
immunoassay results with (he clinical picture, will be pub­
lished later b\ Professor Mudnc 
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of the sample was mixed with 10 μί of human anti-
HBs and incubated for 1 hour at 37 °C followed by 
16 hours at 40C. A sham neutralization was done 
with non-immune human serum as a control on an 
identical dilution series of the same sample. After 
the neutralization procedure each dilution was 
tested according to the screening test procedure. 
Untreated (undiluted) samples were simultaneously 
retested in order to check the result of the screening. 
If read by eye, a titre reduction of at least two 
dilution steps, after anti-НВэ treatment, as com­
pared with the control treatment was considered 
specifically positive. If no endpoint was found, but 
a reduction of colour was clearly visible in compari­
son with the control, the extinctions were measured 
for a final conclusion (see below). Only very strong 
positives had to be retested after making a further 
dilution series of the sample starting at 1:32. Normal 
human serum (free from HBsAg and anti-HBs) was 
then used as diluent in order to avoid non-specific 
binding of coniugate to the solid phase due to the 
absence of sufficient inert proteins. 
If read colorimetrically, reduction of the extinction 
by anti-HB
s
 by at least 50%, in comparison with the 
control, was considered to confirm a specific positive 
reaction. 
DETECTION OF ANTI-HB3 
Serial dilutions of two HB,Ag-containing sera, of 
subtype ay and subtype ad respectively, were made 
in 0·9% sodium chloride containing either 3% 
bovine serum albumin or 10% normal human 
serum proved to be free from anti-HB
s
 and HBsAg. 
Ten microlitres of each dilution was mixed with 
0-1 ml of the serum to be tested for anti-HBs. The 
mixture was incubated for 1 hour at 370C followed 
by 16 hours at 4"C. 
Any reduction of the titre of the HB
s
Ag-contain-
ing sera, when compared with a proper control, was 
regarded as an indication that anti-HBs was present 
in the serum tested. 
ADDITIONAL TECHNIQUES FOR HBsAg 
DETERMINATION 
Radioimmunoassay (RIA):Ausria II (Abbott Labo­
ratories, Chicago, 111, USA) was used according to 
the manufacturer's instructions. Reversed passive 
haemagglutination (rHA): Hepanosticon® (Organon 
Teknika, Oss, The Netherlands) was performed as 
described by Schuurs and Kacaki (1974). 
Subspecificities of HBsAg positive sera were 
determined by immunodiffusion as described by van 
Kooten Kok-Doorschodt et al (1972). 
Results 
SENSITIVITY DETERMINED IN DILUTION 
SERIES 
Serial dilutions of HBsAg-containing serum in 
normal human serum (free from HBsAg and anti-
HBs) were tested by RIA and EIA in a randomized 
order. Each subspecificity ad and ay was represented 
by two different sera. Each positive serum was 
studied using two different normal human sera as a 
dilution fluid. The results are summarized in tables 
I and H and in figure 1. 
SERUM ΡΑΝΕΙ S 
German reference panel 
This panel consisted of 50 samples (two positive sera 
in 20 dilutions each and 10 negative samples). It 
had been previously tested by 34 West German 
laboratories using solid phase RIA (Gerlich et al, 
1976). This panel was tested in our laboratory under 
Dilution1 
factor Ratio 
1 
6 0 
3 3 
2 0 
2 3 
1 6 
2 8 
2 6 
1 8 
1 2 
0 9 
1 I 
2 
4 4 
3 3 
1-9 
1 6 
1 4 
3 4 
2 5 
2 2 
1 5 
1 3 
1 3 
Ratio 
1 
120 
5 5 
3 8 
1 5 
1 4 
9 2 
5 3 
2 3 
2 2 
1 2 
0 9 
2 
9 9 
6 7 
3 1 
1 6 
1 2 
130 
5 6 
2 6 
2 0 
1-2 
0 5 
Eye-reading 
1 
+ + 
± -
+ h 
± -
2 
- + 
-Ч-
-t + 
± -
+ + 
+ + 
2 " 
2 " 
2 " 
2 " 
г
11 
2· 
2' 
2· 
2· 
2"· 
2" 
Tabic I Titration of two different HBsAg positive sera of subtype ay 
'Dilution senes 1 and 2 were made in different normal human sera 
'Naked-eye readines were made by two unbiased individuals 
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Dilution* 
Jul ЮГ 
2" 
2" 
2 " 
2 " 
2 " 
2 " 
2 " 
2 " 
2 " 
г
1
· 
2 " 
2 " 
ЯН 
Rano 
I 
130 
9 2 
4 2 
2 5 
2 I 
1 4 
7 6 
5 5 
2 6 
2 0 
1 4 
1-3 
2 
197 
Il 0 
6 8 
3 1 
1 7 
ι з 
157 
9 4 
4-5 
2 6 
1 6 
I 4 
t/A 
Runo 
1 
180 
5 9 
5 2 
2 6 
2 2 
I 3 
7 5 
3 1 
3 0 
1 5 
n.d 
0 6 
2 
130 
8 8 
4 0 
2 2 
1 3 
I\1 
179 
6 2 
3 8 
2 0 
1 3 
0 7 
Eye reading1 
1 
_,.
 r 
-f-
. L 
. -
І I 
- -
, _ 
-
2 
* -
\ — 
t- — 
\ ~ 
Table II Titration of two different HBsAg positive sera of subtype ad 
'Dilution scries 1 and 2 were made in different normal human sera 
'Naked-eye readings were made by two unbiased individuals 
EIA and Ausria Π 
ad 
ay ad 
diluted in serum 
1 2 1 2 
EIA Δ A ν • 
Ausria П о · о • 
Ratio 
10 I O 3 I O 4 I O 5 
Dilution of HB s Ag containing serum 
1 0 6 
Fig 1 Dose-response curve of HBsAg in EIA (extinction measurement) and RIA (Ausria ¡I). The curves are based 
on data partially presented in tables I and If. The two results of the ad subtype in EIA and RIA are represented by 
the same curve. 
code, which was held by Professor R. Thomssen. 
The results are given in table III. After breaking the 
code, it was seen that the concentration of HBsAg 
ranged from 16 000 ng/ml to 0-03 ng/ml for subtype 
ad and from 10 000 ng/ml to 0-02 ng/ml for subtype 
ay (Gerlich et al, 1976). The EIA technique detected 
at least 10-5 ng/ml of the subtype ad and at least 
2-4 ng/ml of the subtype ay. 
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No. of samples Subtype1 Dilutions1 ng HBiAgiml· RiA(% Λ )* 
Toial 50 
1 -2· 
2.0 
2 " 
2 " 
211.21· 
1 - 2 " 
2 " 
2 " 
2 i > 
2'*-2" 
, 
I 
16 000-23 5 
10 5 
3 7 
1 2 
< l - < 0 0 3 
10000-10 
4 9 
2 4 
< 1 · 2 
< 0 6-<0 02 
< 5 
< 5 
97-100 
94 
78 
15 
6-0 
91-100 
39 
12 
0 
0 
0 
0 
Ψ 
-1-
-
-
+ 
+ 
+ 
± 
± 
Table III German National Reference Panel 
'As reported by Gerlich el al (1976) 
'As repjrted by Gerlich ?r al (1976); percentage οΓ 34 participating laboratories that reported a positive result 
'Colorimetrie reading 
'Contains anli-HBs 
CLB panel 
This panel consisted of 70 HBsAg positive and 
30 HBsAg negative sera, as determined by Ausria II. 
The results obtained in this panel by EIA are given 
in table IV. The sensitivity of EIA (eye reading) 
was found to be the same as that of RIA. 
EIA 
гНЛ 
. 
-
+ 
-
RIA 
70 
0 
65 
5 
0 
30 
0 
30 
Table IV Results of the examination of the CLB panel 
BOB panel No. 2 
All positive samples (32) labelled A, B, and С were 
found to be positive by EIA, even when read with 
the naked eye. Two 'borderline positives' labelled 
(C) and the 16 negative samples of this panel were 
found to be negative in EIA. 
BOB panel No. 3 
All positive samples (17) labelled A, B, and С were 
found to be positive in EIA both by eye reading and 
colorimetrically. Both positives labelled (C), which 
are described by the BOB as Occasionally reactive 
by third generation test methods' (such as RIA), were 
found to be positive in one EIA test and equivocal 
in another. 
The samples labelled D, which are described as 
'non-reactive by current test methods but contain 
low levels of HB,Ag', were found to be negative 
in EIA. 
The samples labelled negative (3) were also found 
to be negative. 
SERA OF ACUTE HEPATITIS В PATIENTS 
Serial serum samples of 14 patients with acute type 
В hepatitis were tested by counter-immunoelectro-
pnorcsis (CEP)1, rHA, RIA, and EIA. 
The HB,Ag subtype was ay in nine patients and 
ad in two, while in three cases the concentration was 
too low for subtypmg. The results obtained are 
presented in table V. 
Week* after 
beginning oj 
overt disease 
1 
2 
4 
6 
8 
10 
12 
14 
16 
dumber of HBsAg-positl 
CEP 
12 
6 
4 
2 
1 
0 
0 
0 
0 
rHA 
14 
14 
13 
11 
7 
2 
2 
1 
0 
RIA 
14 
14 
13 
11 
10 
5 
3 
1 
0 
ve reactions 
HA 
£><·' 
14 
14 
13 
11 
II 
7 
4 
3 
0 
Ext* 
14 
14 
14 
11 
11 
7 
4 }' 
3 
1 J 
Table V Number of positive reactions in 14 patients 
at various times after the beginning of overt disease 
'Eye = reading by naked eye 
'Fxt = readme by extinction at 492 nm 
'All sera in this area where EIA positi vi ι у lasted longer (han RIA 
роыи ііу contained HB^Ag exclusive of subtype ay 
In the final stage οΓ the antigenaemia. some 
patients still reacted positively in EIA, while RIA 
was already negative. This was found in five patients 
Performed by Professor V. Mudnc. 
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if EIA results were measured colonmetncally, and 
in three patients if eye reading was used Six patients 
showed episodes of negative reactions, as shown in 
figure 2 Most serum samples of these patients were 
negative in all tests during these periods In three 
cases, however (patient 13 in week 9, patient 14 in 
week 10, and patient 19 in week 12), the RIA was 
negative while the EIA was true positive In summary, 
EIA was positive in eight sera (colonmetncally) and 
in six cases (read with the naked eye) where RIA 
was negative 
mESH BLOOD DONOR SERA 
Of 679 fresh sera from blood donors, three were 
found to be weakly positive in EIA screening (eye 
reading) None of the three could be neutralized by 
specific antiserum All 679 sera were negative by 
rHA 
Discussion 
The preliminary results obtained with EIA show 
that this new test for HBsAg has a sensitivity that 
compares very favourably with that of RIA 
Titration of HB
s
Ag subtype ad resulted in similar 
dose-response curves for both test systems, while 
the slope of the curve obtained with subtype ay 
was steeper for EIA 
According to the data of the German Reference 
Panel, the detection level of HBsAg in EIA is at 
least 10 5 ng'ml for the ad subtype and 2-4 ng/ml 
for the ay subtype (table III) If the HBsAg concentr­
ation detected by at least 67% of the participating 
Pat no Subtype 
20 ay 
19 ay 
18 ' 
14 ay 
13 ay 
ι ι τ -
Ο S 10 
weeks of trial 
laboratories (Gerlich et al, 1976) is taken as the 
detection level of RIA, this level is in the order of 
3-4 ng/ml for subtype ad and 5-10 ng/ml for subtype 
ay 
This indicates that, with respect to subtype ad, 
the sensitivity of EIA is lower than that of RIA by 
a factor of 2-3 On the contrary, with respect to 
subtype ay, the sensitivity of EIA is about three 
times higher provided that a ratio of ^2·\ (for both 
subtypes) is accepted as a positive cut-off value In 
our view, this small difference in sensitivity towards 
the two subtypes is rather a characteristic of the 
immune reagents than of the test procedure Antisera 
with slightly different subtype specificity profiles are 
now being investigated 
It might be of interest to note here that the one 
'negative' sample found equivocal in EIA (table III) 
but negative in RIA contained anti-HB, (Thomssen, 
Gerlich, and Stamm, personal communication), so 
that one cannot completely exclude the presence of 
HBsAg in immune complexes 
The results obtained with our dilution series 
(tables I and II and figure 1), the CLB panel (table 
IV), and the Reference panels Nos 2 and 3 of the 
BOB confirm our impression that RIA and EIA 
have a similar sensitivity 
From the follow-up of HBs-antigenaemia in 14 
patients with acute hepatitis B, it appears that EIA 
is even somewhat more sensitive than RIA by both 
eye reading and extinction measurcmenls It is of 
interest that all of the six cases in which EIA (eye 
reading) was positive where the RIA was negative 
(table V) were of subtype ay 
Γ 7 . . . Fig 2 Results of longitudinal 
studies in si χ patients with 
hepatitis В shoHing mter-
nut tent periods of HB^Ag-
negative reactions The three 
lines for each patient represent 
the positive results with ЫА 
(both colorimetrie and eye 
reading), RIA, and rHA 
_ _ respectively. From patient 19 
— — no serum sample taken in 
и eek 13 was available for 
1— testing 
15 
EIA 
RIA 
rHA 
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Concerning the interesting observation of the 
reappearance of HBsAg positivity by EIA and/or 
RIA during reconvalescence in six cases (figure 2), 
there were no clinical or biochemical changes observ-
able in these patients which could explain this 
phenomenon (Mudnc and Vukovió, 1975). 
Karvountzis el al (1975) described patients with two 
episodes of hepatitis which, however, were in no 
instance HBnAg-positive in both episodes An inter-
mittent antigenaemia in chimpanzees infected with 
hepatitis В virus was found by Berquist el al (1975) 
in the early course of the disease We are not aware 
of any publication dealing with more than one 
HBsAg positive episode in ' umans during acute 
hepatitis В such as we found This phenomenon may 
be of epidemiological interest, since the majority of 
patients who showed this HBsAg-negative period 
had already been discharged from the hospital as 
'HBsAg-negative'. 
As far as the specificity of the EIA screening test 
is concerned we consider the incidence of three false 
positives found in the group of 679 fresh donor sera 
(<0-5%) to be satisfactory 
The method for confirmation of presumptive 
positives was considered satisfactory A series of 
dilutions of up to 1 32 was, in most cases, sufficient 
to obtain a conclusive result All false positives were 
only weakly reactive in the screening Strong pre­
sumptive positives always turned out to be true 
positive when tested at higher dilutions Thus a 
confirmatory result of all false positives and most 
true positives is available on the day after screening 
We are now investigating a simpler confirmation 
procedure in which the predilution of sample is 
superfluous The method is the same as the screening 
procedure except that an incubation with human 
anti-HBs is inserted after the binding of HBsAg 
from the sample to the solid phase and before the 
addition of conjugate Preliminary results are 
encouraging Details will be presented elsewhere 
Tests for the detection of HB
s
Ag in donor blood 
should be as sensitive as possible (cf WHO Tech­
nical report, 1975) On the other hand, every screen­
ing test should also be as easy and practicable as 
possible As is apparent from our results, EIA 
equals the sensitivity of RIA, thus belonging to the 
most sensitive test systems for HBsAg at present 
available 
The advantages of EIA over RIA are evident. 
Radio-iodmaled reagents have a short shelf life and 
require expensive, rather sophisticated equipment 
for their detection In an increasing number of 
countries the handling of radioactive material and 
the disposal of radioactive waste become subject to 
legal limitations 
EIA has none of these disadvantages but it does 
equal the sensitivity of RIA This is already the case 
when the results are read by the naked eye. If a more 
objective reading and a somewhat higher sensitivity 
are desired, the use of colorimetrie reading may 
contribute to this end 
In conclusion, EIA represents an easy and modern 
answer to the requirement of highly sensitive HBsAg 
detection, especially for less well equipped labora­
tories 
On the basis of the data described above we are 
organizing a multicentre efficacy trial of the test, 
the results of which will be published later 
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Enzyme-Linked Immunosorbent Assay for 
Hepatitis В Surface Antigen 
Gerrit Wolters, Leo P. С. Kuijpers, Fiom the Scteìittfic Development Group of Organon 
Jovan Kaiaki, and Anton H. W. M. Schuurs Inurnatwnal H Г., OÍS, The Netherlands 
A solid-phase enzyme-linked immunosorbent assa> (EI.I.S\), based on the "sandwich" 
princip'e Willi use of microliter plates, was developed foi [he detection of hepatitis В 
surface antigen (HBB \g). Results could be read within one day by the naked eye or by 
colorimeter 'I he detection level was -5-10 ng of HB, Ag ml. The sensitivities of 
ELISA and ratlioimmunoassa) were about the same in dilution series and in a follow-
up study of 19 patients with acute hepatitis В infection In II European medical 
centers whcic >50,()()() samples were tested, ELISA detected significantly more HB, 
Ag-positive samples than a reversed hemagglutination test No significant difference 
in sensitivity between ELISA and radioimmunoassay could be demonstrated. On the 
average, 2.2% of readings were false-positive reactions. Falsely positive samples were 
identified by a confnmatory test 
O u r laboialoiy lias wot keel fot several \eais on 
the development ot a sensitive inummochemical 
technique, the en/vme immunoassay (en/vme-
linked immunosoibent assay, ELISA) [1-3] This 
method has also been studied by many other 
groups of investigators [4]. T h i s paper describes 
the results obtained with a solid-phase FLISA 
based on the "sandwich" principle for the de­
tection of hepatitis В surface antigen ( H B , Ag) 
in blood of donors and in blood of patients with 
hepatitis B. 
Materials and Methods 
TV?; ìengrnts. Details of the preparation of 
the reagents have been desci ¡bed elsewhere [5] 
In biief, the solid-phase antibody consisted of 
Cooke Mitroti ter* plates (Greincr, Nürtingen, 
West Gcimany), the wells of which were coated 
with antibody to H B , Ag (anti-HB,). T h e coated 
plates wet e stored under dry conditions at 4 С 
and were stable for at least 12 months 'I he 
enzyme-labeled antibody (conjugate) consisted 
of anti-HB, coupled to horseradish peroxidase 
We thank Mr J Croesc and Mr l· Rodes for iheir 
technical assistance, jnd Mi S Stulemocr foi his sta 
tentai help 
Please address requests for reprints to Dr Germ Wolters, 
Biochemical Research and Development I aboratoues. Or 
ganon Scientific Development Gump, Kloostcisti.iat 6, Oss, 
1 he Netherlands. 
T h e conjugate could be stored fro/en or lyo-
phili/ed for at least 12 months 
Test pet¡oimance. Thesample (0.1 ml), either 
plasma or serum, was placed in a well of an 
antibody-coated Microliter plate Control sera, 
either containing H B , Ag (positive control) 
or free of H B , Ag (negative contiol), were in-
cluded in each test run. T h e plates were cov-
ered with parafilm and incubated for 2 hr at 37 
С or foi 16-24 hi at room temperature. T h e wells 
wete washed with 0.2 м Tris buffer (pH 7 4) 
containing 0 0 j " ( 1 Τ ween "Io each well 0.1 ml 
of the conjugate solution was added carefully 
T h e plates were covered again and incubated 
for 2 hr at 37 C. T h e wells were then washed 
thoioughlv with the same Tris buffer. 
T h e enzymatic activity was determined by ad­
dition ol 0.1 ml of a freshly prepared solution of 
o-plienylenedumine and titea peioxide to each 
well Aftei г>0 min at room tcmpeia tme the reac­
tion was slopped by addition of 0 05 ml of 4 Ν 
I I J S 0 4 . I he \ellow colot of the reaction pioduct 
was com pai cd with negative controls by the na­
ked eye and colorimeliically by measurement of 
absoibance at 492 inn Coloiimeli ic lesulls were 
(onsideied positive if the signal-to-noise lat io 
was at least 2.1, thai is, the absorbante test was 
at leasl 2 1 times the aveiage absoibance of five 
negative to imols In geneial, leading by e\e ap­
pi oached the sensitivity of the colorimetrie lead­
ing, but was less reliable in borderline cases. 
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CoTifnmatoiy test Samples presumed to be 
positive were treated with h u m a n anti H B , as 
described elsewhere [5] and tested again An al 
ternative neutralization method (based on 
blocking the H B , Ag bound by the solid phase 
antibod) after the first incubation) was also used 
because of Us simplicity and effeclmty [6] T h i s 
method consisted of a first incubation of the nudi 
luted sample in the antibody coated plate for 16-
24 hr at room temperature, a setond incubation 
with human anti H B , for 2 hr at 37 C, and a third 
incubation with conjugate for 2 hr at 37 С A 
sham neutrah/at ion with normal human serum 
instead of h u m a n anti H B , was used as a control 
A visible reduction of the color finally developed 
was considered to represent a true positive sam 
pie 
Additional techniques for determination of 
HR,Ag Radioimmunoassay (RIA) (Ausria I I , 
Abbott Laboratories, Chicago, 111), was used ac 
cording to the m a n u f a c t u r e r s instructions Re 
versed passi\e hemagglutination (RHA) (Hep 
anosticon*, Organon Teknika, Oss, I he Ncth 
crlands) was performed as described by Schuurs 
and Кцсакі [7] Presumptive positive results were 
confirmed by the usual absorption procedure 
Subspecificities of H B , Ag positive sera were de 
termined by immunodiffusion [8] 
Origin of test samples Bureau of Biologies 
(BOB) reference panel no 3 was provided bv 
the Bureau of Biologies, IOCKI and Drug Ad 
ministration, Bethesda, \Id I he first panel of 
the National Reference Centre for Virus Hep 
atitis at the Institute of Hygiene of the Univer 
sily of Gottingen, West Germany, was obtained 
through Prof R Thomssen and Dr W Gerlich 
Results obtained with this panel in Germany 
have been published [91 
Serum samples from 19 patients hospitalized 
with acute viral hepatitis type В were collected 
weekly for 16-19 weeks after the initial svmp 
toms and were made available by Prof V Mud 
rie, School of Medicine, University of Novi Sad, 
Yugoslavia 
Serum and/or plasma of blood donors were in 
vestigated by 11 centers in northwest Europe 
and in southern and eastern Europe 1 he sam 
pies were tested by reversed hemagglutination 
and FI.ISA (eye reading only), and in five centers 
they were also tested by radioimmunoassay Sam 
pies giving discrepant results between test systems 
were sent to us foi further investigation 
Results 
Refeieme panels T h e German reference 
panel consisted of 50 samples (two positive sera 
in 20 dilutions and 10 negative samples) T h e 
concentiation of H B , \g in each sample and the 
lesults of M West German laboratories' solid 
phase RIA were unknown to us before testing 
\\ hen the code was broken, it was seen that 
the concenti ation of H B , Ag in the positive sani 
pies langet! from 16,000 to 0 03 ng/ml for sub­
type ad and from 10,000 to 0 02 ng/ml for sub 
tvpe ay T h e results obtained with the positive 
samples are summarized in table 1 T h e nega 
live samples did not react in ELISA 
For BOB panel no 3, all 17 positive samples 
labeled A, B, and С were found positive in ELI­
SA, bolli by eye reading and colorimeli ically 
Both positive samples labeled С which were de 
scribed by the BOB as "occasionally reactive by 
third generation test methods (such as RIA), 
were positive in one E L I S ^ and equivocal in 
another T h e samples labeled D and described 
table 1 Results of enzyme linked immunosorbent 
assay (ELISA) and radioimmunoassay (RIA) of 
samples from the German National Reference Panel 
that were positive for hepatitis В surface antigen 
(HBS Ag) 
HBS Ag subtype, Percentage Signal to noise 
amount* (ng/ml) positive m RJAJ' ratio in ELISA 
Subtype 
г.гз') 
10 5 
3 7 
1 2 
<1 
Subtype 
ï»10 
4 9 
2 4 
1 2 
<0 6 
ad 
ay 
>97 
94 
78t 
15 
<6 
» 9 1 t 
39 
12 
0 
0 
>2 1 
>2 I t 
1 5-2 0 
<1 5 
<1 5 
>2 1 
>2\ 
>2 1t 
1 5-2 0 
<1 5 
*Data are from [9] 
tPercentdge of 34 laboratories reporting a positive result 
[9] 
t Lowest detectable concentration 
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Figure 1. Dose-response curves of 
radioimmunoassay (RIA) and en­
zyme linked immunosorbent assay 
(EIA) of two sera containing 
hepatitis В surface antigen of 
subtype ad {top) and of two sera 
containing hepatitis В surface anti 
gen of subtype ay (bottom) All 
ratios are the mean of two assays. 
as "non-reactive by current test methods but con­
taining low levels of IIB, Ag" were negative in 
ELISA T h e three samples labeled negative 
were also negative in ELISA. 
Dilution senes. Serial dilutions of H B , Ag-
containing sera were tested by RIA and ELISA 
in a randomized order Subtypes ad and ay were 
represented by two different sera Dilutions of 
eacli HB, Ag containing serum were made in two 
different normal human sera. Afterwards the con 
centration of HB, Ag in each dilution was deter­
mined with the German reference panel as a stan­
dard The results obtained for subtypes ad and ay 
are shown in figure 1. 
The detection limits of ELISA and RIA (ra­
tio of 2.1) were found to be 2-3 ng of subtype 
ad/ml in both test systems, 2-3 ng of subtype 
ay/ml m ELISA, and 3-4 ng of subtype ay/ml in 
RIA. 
Sera of patients with acute hepatitis B. Serial 
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samples of sci um of 19 patients with acute hepa-
titis 15 were tested in countcrimmunoelcctroplio-
resis (ChP, performed by Prof V. Mudric, No\ i 
Sad, Yugoslawa), RUA, RIA. and ELISA. T h e 
H B , Ag subtype was ay in 13 patients and ad 
in two; in four cases the concentration was too 
low for subtyping. 
Results in CEP, the least sensitive detection 
method used, became negative first in all patients, 
after about 3 5 weeks on average. T h e number of 
patients negati \e by CEP but still positive in 
RHA, RIA, and ELISA (colorimetiic leading) 
dui mg convalescence is presented in figuie Ï. 
Antigenrmia in some patients was detected long-
ei in F.LISA than in RIA The H B , Ag subtype 
in these patients was unknown in one case and 
ay in all others. In only one patient did RIA 
lemain positive while ELISA gave a negative re-
sult. In this tase the subtvpe (otild not be de-
tei mined. 
I he number of positive reactions increased 
duiii ig the final stage (weeks II and 15) because 
seven patients showed a iccuitcnce of HBH Ag 
(figuie V) Most samples of sei urn from these pa-
tients weie negative in all tests d in ing these 
penods Moieovei, in tlnee tases (patient no. 13 
in week '), paiieni no I 1 in week 10, and patient 
no 1!) in week 12) the RIA was negative while 
НИ, \g was still detened, at least loi a ρ,ut of 
the peiiod, by ELISA In summaiy, ELISA was 
positive m 17 samples liom 10 patients when 
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Figure 2. Préseme of hepatitis В surface antigen 
(I1BS VO m 19 patients with acute hepatitis B, as 
detected by three methods: reversed hemagglutina­
tion ( · · · ). radioimmunoassay ( ), and lolon-
metric reading of the enzyme-linked immunosorbent 
assa> ( ). I he first sample giving a negative result 
in tounlerimmunoclcctrophoresis (ChP) was taken as 
Lhc starling point for each patient. 
Figure 3. Intermit lent presente of 
hepatitis β surface aniigen in 
seven palienls, as delected 
b\ counicriniimr.iocle< Irophoresis 
( ' / / / / ' ' ) , en/v me linked immuno­
sorbent assay ( - ), radmiminuno 
assav ( ), and reversed hem 
agglutination ( · . ) Verncal line 
indie ates end of testing. 
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RW WAS neça tne , while HU, Ag was tletecied in 
one sample onl) h) RI \ "I he с о і о п т е і г к 
і е . к і т ц was |X)siti\e in three samples that were 
not considered positive h) e\e 
bensì I mi ty with donoi ieia Companson be-
tween ELIbA and RHA In total, I l "ЮТ sera 
οι plasmas of blood donors were tested m RH-V 
and FI ISA (table 2) U the test lesults weie 
disci epam, the RIA result was taken as deci 
s u e No significant dilTeience in sensitivi^ be 
twecn R H A and ELISA could be demonstrated 
on the basis of results in northweslei η t u r u p e , 
because of the small number of positive samples 
in this donoi populat ion Howevci, in southein 
and eastern Euiope the sens i tmt) of EI ISA was 
sigmficanth higher than that ol R H A 
Comfmiuon of ELISA u4th RIA In total, 
27,122 donoi sera (οι plasmas) weic tested in 
ELIS \ and RI \ Aftei confiimation of the sam­
ples positive in Ы ISA sci celling, these samples 
weic com pai cd with samples positive in RIA 
scieening (not all presumptive positive samples 
weie available for (onñimat ion in RIA) Re-
sults were positive in both tests foi 112 samples 
and negative in both tests foi 26,939 samples Re-
sults weie disciepant foi 41 samples, and all ol 
these samples that weie available were retestcd 
ELISA was negative and RIA positive foi 11 
samples I he piesence of H B , Ag was confiimed 
in seven One sample was nol confiinied as posi 
live b) RI \ Insuflicient material was available 
for the other three samples F l I S V was posi 
uve and RIA negative for eight samples I he 
piesence of H B , Ag was (onfumed in two of these, 
Table 2 Comparison of reversed hemagglutination 
tests (RII \) and en/уте linked immunosorbent assa> 
(LI ISA) of samples from blood donors after «onfir-
mation of presumptively positive samples by their 
corresponding conlirmatory tests and by radioim 
munoassay (RIA) 
Part of E u r o p e N o p u s i u v i N o positive 
(no l i s t e d ) by К И Л by ELISA 
N o r t h w e s t e r n ( 3 2 , 4 9 0 ) 4 7 50 
S o u l h e r n a n d eastern 
( ¿2 ,017) 4 4 5 6 6 8 
t o t a l ( 54 ,507 ) 4 9 2 718 
NOTl· If bo th RHA ind I· L ib λ wer« sperifically positive, 
RIA was n o t pt ι formi d in somi casis b u t wab ι onsidi π d to 
bt positive 
bin could not be dciecied in another two sam­
ples Foui samples weie not available foi con 
fiimaloiv testing ELISA was inconclusive for 22 
samples that weie negative bv RIA Most (19) 
of the inionclusive results weie found in one 
centci All 22 turned out to be negative aftei 
fuithei e t a m i n a t i o n 
bpeafiaty m donoi «?ια T h e percentage of 
all samples tested that reacted in the screening 
but turned out to be nonspecific or negative aftei 
the propel confirmation test was 1 4 % for R H A 
and 2 2 % for ELISA T i n s indicates that ELISA 
si ieening is less specific than R H A screening It 
should be mentioned here that two centers found 
lathei high peicentages of false-positive results 
in the scieening (r>"() ami 1'>"<,), wheieas otheis 
lound less than 3 0 0 
In three (enters (including the two mentioned 
above), moie than 9 0 " 0 of the piesumptive posi 
uve samples weie negative when letcsled This 
lendenev could p a r t h be ascnbed to a latk of 
expci lence at the Ixginiiing ol the m a l , u was 
lepoited that the specidcitv inipiovcd during 
the lii.il It was also obseivcd in some cenici s 
thai lieshlv taken blood samples gave a highei 
liecjuencv of lake positives in the scieening 
( M 0 "
o
) Such sei a did not l e a d positively upon 
letesimg aftei one oi moie davs of stoiage 
Discussion 
O u r results showed that ELISA is a highl) sen 
suive technique foi the detection of H B , Ag "I he 
detection level for H B , Ag in l· LISA was =£105 
n g ' m l foi the ad subtvpe and ' 2 1 n g ' m l foi 
the ay subtype, these values were found by a di­
rect test of the Gei man refeience panel I 'smg 
RIA, the majoiuv (>67 < ' 0 ) of 31 German laboia 
tones detected 3-4 ng of subtvpe a d / m l and 
')-I0 ng of subtype ay/ml This finding indicat­
ed that with respect lo subtvpe ad, the sensitivity 
of EI ISA mav have been slightly less lhan that 
of RIA O n the othei hand, with respect to sub 
ivpe ay, I:LISA was somewhat more sensitive 
lhan RI \ I he resuhs obtained with the refer 
enee panel no 3 of the BOB indicated 
that LLIS \ met the standaids for a "third-gen 
elation test 
When sci urn loiitaiiiing H B , Ag of subtvpe 
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ad was titrated, similar dose response curves 
weie lound in ELISA and RIA T h e ay subtype 
showed a steepei curve in ELISA than in RIA 
T h e cutoff value (2 I) in ELISA coiresponded 
with about the same concentiation oí H B , Ag 
for ay as for ad (2-3 ng/ml) With regard to ad 
this result differs from the data obtained with 
the direct test of the German reference panel A 
shchll) higher detection limit was found in RIA 
for ay (3-4 ng/ml) than for ad (2-3 ng/ml) 
In the follow up study of H B , antigcncmia in 
19 patients with acute hepatitis B, ELISA ар 
peared to be somewhat more sensitive than 
RIA None of the 10 patients whose sci ι were 
positive in EI ISA and negative in RIA showed an 
H B , Ag subtyjie ad Again F U S A appealed to 
be slightly more sensitive than RIA for ay In 
our view, this was a characteristic of the immune 
reagents rather than of the tesi system Anusera 
with a different piofile of subtype specificity 
might have given somewhat different results 
T. he concentration of H B , Ag apparently de 
(reased dur ing convalescence, since R H A (dc 
tection level ~100 ng/ml) stayed positive longer 
in most patients than did CEP, and EI ISA and 
RIA still detected H B , Ag aftei R H A had be 
come negative A further decrease of the level of 
H B , Ag dur ing convalescence was indicated by 
the increasing number of negative results in 
E L I S \ and/or RIA However, the r e c u n t n e e of 
H B , Ag in seven patients (figure 4) suggested 
that H B , Ag had not yet disappeared, but had 
been reduced tcmporanlv to an undetectable lev 
el T h e r e may still have been replication of the 
hepatitis В virus during the H B , Ag free pen 
ods 1 his phenomenon may also be correlated 
with the production of anti I I B , T h e presence 
of anti H B , will therefoie be investigated m fu 
lure studies 
T h e results of the multicenter trial with more 
than 50,000 donoi sei a or plasmas also demon 
strated that ELISA was a highly sensitive sctecn 
ing test foi I I B , Ag EI ISA was diiectly com 
pared with R I A in more than 25 000 samples 
T w o factors might have influenced that part of 
the study in favor of RIA first, moie than 20 000 
of the donors tested were in northwestern Europe, 
where the H B , Ag subtype ad is predominant 
and second confirmed ELISA results were com 
pared with results of RIA screening (for prac 
tirai leasons) In spite of this, the study suggest 
ed that FLISA can indeed compete with RIA 
A much larger number of donor sera would be 
needed for establishment of any significant dif 
ferente between the two test methods 
T h e ELISA screening showed a relatively 
low specificity in this trial (2 2 % ol the screening 
results weie falsely positive) Pailiculailv in 
centers showing high nunibers of false positive 
results, the majoiity ( > 9 0 ο
ο
 in three centcis) ap 
peared to be untepeatable positives Lack of ex­
perience with the test was piobabl) one of the 
causes Pait icular l) , the washing proceduie, the 
pipetting of conjugue and the toveung of the 
¡ilates dur ing incubation were critical proce 
duies Τ he phenomenon ol a high numbci of 
false positive results in screening of fresh sei a was 
not lound when we ourselves tested 679 fiesh 
donoi sera [5] 
On the oilier hand, a small number of the 
false positive reactions appealed to be caused 
by peisislent nonspecific fictois I b i s type of 
false [M)sitive was also reactive upon retesting 
and could not be neut iah/ed by hum in anti 
H B , One of these nons]>ecific factors is likely to 
be the ihcumatoid factor, we found that about 
2 0 % of about 500 sei a containing iheumatoid 
factor ι esultili in nonspecific icactions in Η IS \ 
scieening (authors unpublished results) Such 
reactions weie always weak (latios <5) Aftei 
the confimiatoiy test which should never be 
omitted in an) test foi H B , \g ELISA is highly 
specific 
lests foi the detection of H B , Ag m donoi 
blood should be as sensitive as possible and a 
high sensitivity is also u n p o i t m t foi the follow 
up of patients with acute hepatitis В A screen 
nig test should also be eas\, piacticablc and in 
expensive ELISA is as sensitive as R I A and 
EI ISA does not have the disadv images of RI \ 
such as the shoit shelf lile of one of the leagents 
the disposal of ladioactive w iste and the need 
for sophisticated ccpupinent FLISA icsults can 
even be lead with the naked eve If a moie 
objective reading (and, in some cases a slightly 
higher sensitivity) is desired, a colorimetrie mea 
suiemeiii can be peifoimed 
In conclusion, LI ISA ausweis the l equnenicnl 
for a highly sensitive method of delecting H B , 
Ag in blood from donoi s and patients and it 
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is also suitable foi modesti, equipped labora­
tories. 
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Serological evidence of presence of HBsAg 
undetectable by conventional radioimmunoassay 
in anti-HBc positive blood donors 
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From the Public Health Laboratory and the Red Cross Blood Bank1, Municipal Hospital, 6800 EG Arnhem, 
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SUMMARY Sera from two blood donors, one of whom was implicated in a case of post-transfusion 
hepatitis B, were found to be positive for anti-HBc and negative for HBsAg by conventional 
radioimmunoassay and were retested for HBsAg after concentration (pepsin digestion and 
polyethylene glycol precipitation) The presence of occult HBsAg was confirmed in both These 
observations have implications for blood transfusion, and wider studies of anti-HBc in blood 
donors are recommended before the introduction of routine screening for anti-HBc and exclusion 
of the positive donors from blood donation. 
Post-transfusion hepatitis В has been reported oc­
casionally in recipients of blood negative for HBsAg 
by radioimmunoassay (Hollinger et al, 1973, 
Koretz et al, 1973) A possible explanation for such 
occurrences may be a relative insensitivity of the 
currently most sensitive techniques for HBsAg 
detection Gerlich et al (1976) have reported the 
sensitivity of radioimmunoassay to be between 1 -2 
and 2 4 ng HBsAg/ml, while the sensitivity of the 
enzyme-immunodssay vanes between 2 4 and 
10 5 ng HBsAg/ml (Wolters et al, 1976) The 
description of a new antigen/antibody system by 
Almeida et al (1971), comprising the cores of Dane 
particles and antibodies to them (HBcAg and anti-
HBc), has provided an additional tool for detecting 
the presence of hepatitis В virus (HBV) markers 
Hoofnagle et al (1973, 1974) have proposed an 
hypothesis, according to which a positive anti-HBc 
as a sole marker of HBV infection may be an indi­
cator of a continued multiplication of HBV in liver 
cells, with a possible intermittent viraemia, account­
ing thus for the occurrence of post-transfusion 
hepatitis В in some recipients of such blood In none 
of such donors, however, was there evidence of 
HBsAg in circulation 
We report the results of an attempt to determine 
the presence of HBsAg in quantities undetectable 
by conventional radioimmunoassay screening in two 
blood donor sera in which the sole HBV marker was 
a positive test for anti HBc One of these donors was 
implicated as a probable cause of a post-transfusion 
hepatitis B; the other was tested for anti-HBc in 
addition to the routine screening for HBsAg 
because he had an episode of hepatitis in anam­
nesis 
Material and methods 
TESTS FOR HBV MARKERS 
HBsAg and anti-HBs were detected by radio­
immunoassay (Ausria II and Ausab, Abbott Lab­
oratories, North Chicago, 111, USA) The specificity 
of HBsAg positives was determined by neutralisation 
with human anti-HBs HBeAg and anti-HBe were 
detected by double immunodiffusion in agarose 
Anti-HBc was detected by indirect immunofluor­
escence, using post-mortem human liver rich in 
HBcAg as substrate, as described by Kater and 
Vögten (1976), with a modification using formalin-
fixed tissue The specificity of this technique was 
controlled by complete abolition of anti-HBc 
positivity of a known positive serum after absorption 
with a suspension of HBcAg positive liver tissue 
(other than the substrate), while the absorption with 
anti-HBc negative liver suspension had no effect 
DETERMINATION OF HBSAg IN QUANTITIES 
UNDETECTABLE BY CONVENTIONAL 
RADIOIMMUNOASSAY 
(hereafter referred to as 'occult HBsAg'). 
The technique described by Harris et al (1977) was 
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used, consisting briefly of sequential pepsin diges­
tion of non-HBsAg proteins at low pH and poly­
ethylene glycol precipitation of remaining HBsAg. 
This technique claims an increase of sensitivity in 
subsequently performed radioimmunoassay by at 
least a factor 100. The sera before the application of 
this procedure and the resulting material were tested 
by Ausria II. The specificity was confirmed by 
neutralisation with human anti-HBs. 
P A T I E N T A N D D O N O R S 
Posl-iransjusion hepatitis В. A 41-year old woman, 
who underwent vaginal uterus extirpation, devel­
oped classic acute hepatitis В with jaundice and 
positive HBsAg about 130 days after a transfusion 
of four units of blood from donors negative for 
HBsAg by radioimmunoassay at routine screening. 
The original serum samples of the four implicated 
donors (Nos. W0869, W9365, V0472, and 13-2483) 
were retrieved from the serum collection kept at 
-20'1C, retested for HBsAg and—in addition to 
this—tested for other HBV markers (anti-HBs, 
HBeAg, anti-HBe, and anti-HBc). The one positive 
for anti-HBc was also tested for occult HBsAg. 
An occasional anti-HBc posit ι ve donor. This donor (No. 
11055/77) was excluded from giving blood on the 
basis of his anti-HBc positivity and an episode of 
hepatitis in anamnesis. He was also tested for other 
HBV markers, along with testing for occult HBsAg. 
A donor false-positive for HBsAg. The serum of this 
donor (No. 22076/78), false positive for HBsAg by 
radioimmunoassay, was used as a negative control in 
testing for occult HBsAg. 
Results 
The results of tracing the donor presumably re­
sponsible for the post-transfusion hepatitis В are 
shown in Table 1. 
One of the four blood donors implicated in the case 
of post-transfusion hepatitis В (donor No. 13-2483) 
was found, of all the HBV markers tested, positive 
only for anti-HBc. This donor was bled again, more 
than six months after the original donation, and 
again found positive only for anti-HBc. This donor 
had no hepatitis episode in anamnesis. Her blood 
had previously (more than six months before the 
donation in question) been given to another recipient. 
This recipient was traced and his serum found 
to be negative for all the HBV markers tested. 
The results of testing for occult HBsAg are shown 
in Table 2. In the sera of both anti-HBc positive 
blood donors a reactivity for HBsAg was detected 
after concentration. The neutralisation with human 
anti-HBs reduced this reactivity by 72-85%. The 
addition of normal human serum devoid of anti-HBs 
activity had no effect. In contrast, occult HBsAg 
could not be detected in the control serum (No. 
22076/78) which was false-positive in HBsAg 
screening. 
Table 1 Tests for HBV markers in four donors implicated in a case of post-transfusion hepatitis В 
Serum 
Donors 
W 0869 
W9365 
V0472 
13-2483 
Recipient 
transfusion 
26 July '77 
Table 2 
Serum No 
13-2483 
11055/77 
22076/7* 
Date 
25 July '77 
25 July *77 
25 July '77 
25 July '77 
2 heb '78 
7 Jan '78 
Results of testing for 
Tests for usual I 
antt-HBc 
no 
5120 
N e g a n e 
Routine screening 
HBsAg 
Negative 
Negative 
Negative 
Negative 
Negative 
- + 
occult HBsAg in 
iB У-markers 
anti-HBs 
Negative 
Negative 
Negarne 
Additional tests 
anti-HBs 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
HBeAg 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
anti-HBe 
Negative 
Negative 
Negative 
Negative 
Negative 
Negative 
two anti-HBc positive blood donors 
HBs 
ratio 
0 7 
I 1 
11 0+ 
ι Auwa /I* 
Tens Jor occult HBsAg 
ratio Аичпа Π 
after (ontentration 
1 S 
4 7 
1 2 
antt-HBc 
(rectpr titre) 
Negative 
Negative 
Negative 
320 
160 
5120 
bpeafii ¡tv 
( 0 0 ipm decrease)9 
72 
16 
•Regarded specific if „• 50° , , + False positive m conilimaiion lest, tPegarited postme if 
Discossion 
Although a pre-transfusion serum sample from the 
recipient of transfusion who subsequently developed 
hepatitis В was not available, it seems acceptable 
to assume that donor 13-2483 (Table 1) was the 
cause of this infection Anti-HBc persisted in the 
donor for at least 6 months after the blood donation 
and the result of testing for occult HBsAg, however 
low the ratio (see Table 2), seems to be specifically 
confirmed Aside from the results of Hoofnagle et al 
(1973, 1974), and more recently of Lander et al 
(1978), who reported post-transfusion hepatitis В 
after transfusions of anti-HBc positive, HBsAg 
negative blood, it has been shown that persons with 
positive anti-HBc (HBsAg negative in blood) may 
have both HBsAg and HBcAg in liver cells (Ray et 
al, 1976, Kojima et al, 1977) Depending on some 
extraneous factors, such as immunosuppression, 
reactivation of hepatitis В has been observed, eg, in 
renal transplant patients whose sole marker of HBV 
infection was a positive anti-HBc (Nagington et al, 
1977) 
Our results on the determination of occult HBsAg 
in blood donors, negative for HBsAg by convention­
al radioimmunoassay, whose sole marker of HBV 
infection is a positive anti-HBc, seem to support the 
hypothesis of Hoofnagle et al (1973, 1974) After 
concentration the occult HBsAg had apparently been 
detected in at least one of the two sera (No 11055/77, 
Table 2) The specificity for HBsAg, as far as the 
serological criteria are concerned, has been confirm­
ed in both sera It is desirable to obtain more such 
data before any definite conclusion is reached 
Testing for the presence of HBsAg and Dane 
particles by electron immune microscopy in such 
concentrates is warranted 
The reported association of anti-HBc positive 
blood with infectivity for HBV (Hoofnagle et al, 
1973, 1974, Lander et al, 1978) is highly suggestive 
However, in view of the practical consequences for 
blood banking, extensive retrospective studies of 
anti-HBc in blood donor populations, possibly 
combined with attempts to detect occult HBsAg 
in anti-HBc positive samples, and the consequences 
in recipients of such samples, are needed before a 
definite conclusion is reached on the introduction of 
routine screening of blood donors for anti-HBc and 
exclusion of the positive ones from donation 
We are indebted to Dr Ρ Meulendijk and Dr H van 
Leusden, of the St Elisabeth Hospital, Arnhem, 
for signalling the case of post-transfusion hepatitis В 
The technical assistance of Miss J Bijkerk and 
Miss J В G Hietkamp is gratefully acknowledged 
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INTRODUCTION 
Soon after description of a new antigen-antibody system in HBsAg posi­
tive hepatitis (Almeida et al.,1971) consisting of the core of hepa­
titis В virus and antibodies to it (HBcAg and anti-HBc),it became an 
interesting subject of a large number of studies. 
Hoofnagle et al.(1973) have proposed that anti-HBc as a sole positive 
marker of infection with hepatitis В virus (HBV) may be found either 
in the early convalescence from HBV infection,or may indicate a chro­
nic carrier state with subdetectable levels of HBsAg.This latter po-
ssibilityjif confirmed,could partially account for the failure of era­
dicating post-transfusion hepatitis В after excluding all HBsAg posi­
tive donors by the use of currently most sensitive tests for HBsAg, 
such as radioimmunoassay (Hollinger et al.,1973). 
A number of techniques for detection of anti-HBc have been described, 
ranging from immune electron microscopy (Almeida et al.,1971),through 
counterelectrophoresis (Cohen and Cossart,1977),indi reet immunofluo­
rescence (Brzosko et al.,1973) to radioimmunoassay (Purcell et al.,1973) 
In spite of potential importance of testing blood donors for anti-HBc, 
this was not done on a larger scale,due to the technical difficulties 
and lack of a readily available standardized tests.One of the few avai­
lable studies in a substantial number of blood donors (Overby et al., 
1976),reports anti-HBc prevalence of 7,3% in 3929 plasmapheresis do­
nors and 3,2% in 1049 volunteer blood donors. 
Recently,a commercial radioimmunoassay kit for anti-HBc was made avai­
lable under the name of CORAB (Abbott Laboratories,North Chicago,II., 
U.S.A.). 
We have compared this radioimmunoassay and the indirect immunofluore­
scence method for anti-HBc in a group of sera with known HBV markers. 
Thereupon,a group of blood donors negative for HBsAg was tested with 
this new radioimmunoassay for anti-HBc in a pilot study on the preva­
lence of this HBV marker in the population of volunteer blood donors 
in this part of Europe. 
55 
MATERIAL AND METHODS 
Blood donors.Sera from 2000 healthy volunteer blood donors,negative 
for HBsAg by radioimmunoassay were included into this study. 
Determination of HBV markers.HBsAg and anti-HBs were determined by 
radioimmunoassays (respectively AUSRIA II and AUSAB,Abbott Laborato-
ries).HBeAg and anti-HBe were determined by double immunodiffusion 
in agarose.Anti-HBc was determined by two methods: indirect immuno-
fluorescence (IF) and radioimmunoassay (RIA).IF technique was perfor-
med as described by Kater et al.(i 976),with the modification of using 
human formalin-fixed liver tissue rich in HBcAg as substrate.The speci-
ficity of positive results was controlled by differential absorption 
of such sera with human liver tissue homogenates obtained from HBcAg 
positive and negative livers (Katchaki et al.,1978). 
Radioimmunoassay for anti-HBc (CORAB,Abbott Laboratories),was per-
formed according to the manufacturer's instructions.Briefly,this is 
1 25 
a competitive radioimmunoassay in which I-labelled human anti-HBc 
competes with the test-serum for HBcAg bound onto the solid phase. 
For purposes of comparison,we have expressed the positive results also 
. cpm samóle -¡±.¡.¿.1.1. 
as a ratio c τ c τ г · Having in mind that this is 
mean cpm positive control 
a competitive technique - the lower the ratio - the higher is the po-
sitivity of the test sample. 
Set-up of the study.The comparison of RIA and IF was done on a panel 
of 56 sera known for HBV markers. 
The group of 2000 blood donor sera to be tested for anti-HBc by RIA 
was composed upon screening the sera for HBsAg by radioimmunoassay 
and collecting the negative ones for further study.These sera were 
tested by RIA for anti-HBc;the positive ones were re-tested by RIA, 
and only those found reproducible were accepted as positive.All anti 
-HBc positives by RIA screening were also tested for anti-HBc by IF. 
Whenever a sufficient volume of positive sera was available,the spe­
cificity was controlled by differential absorption and retesting in 
both tests (whenever applicable). 
All anti-HBc positive sera were also tested for anti-HBs by 
AUSAB,and for anti-HBe by double immunodiffusion in agarose(lD). 
A control group of 58 donor sera negative for anti-HBc was also 
tested for anti-HBs. 
As many anti-HBc positive sera as possible (depending on the se­
rum volumes available) were tested for "occult" HBsAg (Katchaki 
et al.,1978) after concentration (Harris et al.1977). 
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RESULTS 
The comparative results of RIA and IF for the detection of anti-
HBc in the panel of 56 sera are shown in Table I.RIA was found 
significantly more sensitive than IF ( In the binomial test,2-sided 
Ρ value was 0,015). 
The specificity of IF results in this group was confirmed after 
differential absorption.At the time of their testing in RIA,quan­
tity of these sera was insufficient for such control. 
The results of testing 2000 HBsAg negative blood donors for anti-HBc 
by RIA.qnd of subsequent testing(of anti-HBc positives) for anti-HBs 
are shown in Table II, 
The results of comparative testing of these sera for anti-HBc in 
IF.and the respective results for anti-HBs are given in Figure 1. 
The outcomes of specificity testing of anti-HBc positives are 
shown in Table III.In all 24 RIA positive and 17 IF positive sera 
tested,the specificity of the positive anti-HBc outcomes was con­
fi rmed. 
The comparison of prevalence of anti-HBs in 46 anti-HBc positive 
and in the control group of 5Θ anti-HBc negative donor sera,re­
sulted in finding 37/46 (80,4%) anti-HBc positives simultaneously 
positive for anti-HBs.Only one of the 58 anti-HBc negative sera was 
found positive for anti-HBs.The difference between the two groups 
is statistically significant ( P<0,0'\). 
Twelve anti-HBc positive donor sera have been concentrated and 
tested for "occult" HBsAg by radioimmunoassay.Nine of them were 
simultaneously anti-HBs positive,two were anti-HBc positive only, 
and one was anti-HBc negative in the repeated RIA for anti-HBc 
(Table IV).All twelve cencetrates were found weakly positive for 
HBsAg in the screening test (ratio 2,1).Only one (No.10) approa­
ched the criterion for specificity confirmation (50% reduction 
of cpm after neutralization with human anti-HBs.Two others (Nos.6 
and 7ishowed a reduction of ^  20%. 
Testing of anti-HBc positive sera for anti-HBe by ID resulted in 
none detected positive for anti-HBe.It should be stressed here 
that the relative sensitivities of the two methods used (RIA for 
anti-HBc and ID for anti-HBe) differ to a high extent. 
A.HBsAg positive sera B.HBsAg negative/anti-HBs positive sera 
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Table I.rCompanson of radioimmunoassay and indirect immunofluorescence for anti-HBc in 56 sera 
with known HBV markers 
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Α. 
2000 HBsAg negative 
blood donors 
1-st RIA screening: 
5Θ anti-HBc positives 
(2,9%) 
F. 
Re-
46 
(2 
-test 
anti 
3%) 
mean ra 
ing 
-HBc 
tio 
screening = 
in RIA. 
positives 
in RIA 
1 9 
Η. 
Anti-HBs: 
9 anti-HBs negatives 
(0,4%) 
1942 anti-HBc negatives 
(97,1%) 
D. 
Re-testing in RIA: 
12 anti-HBc negatives 
(0,6%) 
mean ratio in RIA 
screening = 4,4 
E. 
ant ι 
3 
8 
1 
an 
an 
no 
-HBs: 
ti-HBs 
ti-HBs 
t done 
+ 
-
Anti-HBs: 
37 anti-HBs positives 
(1.9%) 
Table II.: Results of testing 200C blood donor sera for anti-HBc 
by radioimmunoassay and of the subsequent testing of 
anti-HBc positives for anti-HBs 
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A. Reproducibly positive anti-HBc (RIA) В. Negative in RIA ге-teeting 
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О anti-HBc posit ive (RIA), negative in IF; anti-ΗΒβ negative 
О " " " - " - (RIA/IP); anti-HBe negative 
(S) - " - - " - - " - / anti-HBe posi t ive 
• anti-HBc posit ive (RIA only) / anti-HBs posi t ive 
0 not available for IF tes t ing 
Figure 1 : Anti-HBc s c r e e n i n g p o s i t i v e s by RIA.Resul ts of r e - t e s t i n g by RIA, 
t e s t i n g f o r anti-HBc by IF and t e s t i n g f o r ant i-HBs 
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anti-HBc 
Number of 
sera 
Specificity control after 
differential absorption. 
Specific positive in: 
RIA IF 
RIA pos./IF pos. 17 
RIA pos./IF pos. 6 
RIA pos./IF neg. 1 
Total 24 
17 
6 
1 
24 
17 
Not done 
Not done 
( screening neg.) 
17 
6 sera not available for IF control 
Table III:Results of specificity control after differential 
absorption and re-testing of 24 anti-HBc positive 
donor sera. 
Serum No. HBV markers in serum 
(HBsAg negative) 
HBsAg testing (RIA) in concentrates 
Screening Confirmation 
cpm sample ( % cpm change after neu-
cpm neg.control tralization with human 
anti-HBs) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
1 2 
a n t i - H B c p o s i t i / a n t i - H B s p o s i t i v e 
a n t i - H B c p o s i t i v e / a n t i - H B s n e g a t i v e 
a n t i - H B c i r r e p r o d u c i b l e / a n t i - H B s 
p o s i t i v e 
223 /51 
381 /51 
225 /51 
388 /51 
320 /51 
305 /51 
288 /51 
385 /51 
378 /51 
340 /51 
218 /51 
3 0 8 / 5 1 
+ 
+ 
-
: 
-
-
+ 
+ 
0 
3 3 
1 6 
8 
4 , 7 
21 
2 8 
1 5 . 6 
48 
49 
4 . 5 
2 8 
Table IV: Screening and confirmation RIA results for "occult HBsAg in concentrates of 
donor sera positive for anti-HBc 
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DISCUSSION 
Comparison of sensitivity of the two methods for anti-HBc detec­
tion shows that RIA is significantly more sensitive than IF in 
a group of 20 HBsAg positive sera,where a positive outcome for 
anti-HBc is to be expected (Table I A).The same conclusion follows 
in 20 anti-HBs positive sera,where a positive anti-HBc result is 
not unexpected (Table I B).It is somewhat puzzling why,in the 
light of the higher sensitivity of RIA.one serum of the six anti-
HBc positives in IF was missed by RIA (Table I C). 
As far as the specificity of RIA is concerned,it seems that the 
presence of anti-IgG activity in tested sera does not create a ma­
jor problem (only 1/10 anti-IgG positive sera gave a positive re­
sult in RIA - Table I C). 
As for the technique of choice for a large-scale anti-HBc testing, 
RIA is significantly more sensitive and not less specific than 
IF (Tables I and IIl);it is easier to perform and gives objective 
reading of results.However,means of specificity control for RIA 
still have to be provided by the producer. 
Screening of 2000 sera of blood donors negative for HBsAg resulted 
in 1942 (97,1/4) in a negative RIA outcome for anti-HBc (Table II B). 
Out of 5Θ (2,9%) anti-HBc positives in RIA screening (Table II C), 
12 were not found reproducible by RIA re-testing (Table II D). 
The difference in the degree of positivity between these two 
groups was considerable (Figure l).The mean ratio's of these two 
groups were 1,96 and 4,4 respectively.The number of anti-HBc strong­
ly positives (ratio < 2) was significantly lower in the screening 
test (P < 0,02) in the group turning anti-HBc negative on re-testing. 
It is of interest to note here that of the 11/12 (Figure 1 B) sera 
irreproducibly positive in RIA,which were available for IF testing, 
none was found positive for anti-HBc by IF.On the other hand,of the 
46 sera reproducibly positive in RIA (Table II F),43 were available 
for further testing in IF and 33/43 found positive.The IF technique 
missed,thus,23% (10/43) sera anti-HBc positive by RIA.again confir­
ming the higher sensitivity of the latter method (Figure 1 A). 
The most interesting group of anti-HBc positive donors is the one 
in which anti-HBc is,apparent!y,the only positive HBV marker 
(Table II H,and Figure 1 A).Comparison of RIA and IF in this group 
shows that out of 8/9 such sera available,? were also recognized 
as anti-HBc positive by IF 
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Another relevant aspect in this group of blood donors is the inter­
relationship of the antibodies to the three HBV antigens (anti-HBc, 
anti-HBs and anti-НВ ).The question of whether anti-HBs positive 
donors could transmit hepatitis В has been extensively studied in 
the past.A general consensus has been reached (based on HBsAg/anti 
-HBs testing and follow-up of recipients) that anti-HBs positive do­
nors do not carry a higher risk of transmitting hepatitis В in com­
parison to the ones negative for this antibody (Goldfield et al., 
1975).Since anti-HBc has not been considered in this respect at 
that time,the knowledge of its presence in such sera adds a new -
as yet not fully understood dimension to this question.Such is the 
case in the vast majority of our donor sera positive for anti-HBc, 
since 37/46 anti-HBc positives (80,4%) have been found simultane­
ously anti-HBs positive.Whether such blood carries a higher risk 
of transmitting hepatitis В than the one positive for anti-HBs only, 
still remains to be seen. 
Our inability to detect any of anti-HBc positive donors simultaneous­
ly positive for anti-HBe is not surprising,considering the low sensi­
tivity of ID technique.The answer to this question must await the 
availability of new sensitive methods for HBeAg and anti-HBe deter­
mination, which are still under development. 
If the hypothesis of Hoofnagle et al.(i 973,1974) can be confirmed, 
the blood of donors positive for anti-HBc (as a sole HBV marker?) 
might be able to cause post-transfusion hepatitis В in susceptible 
recipients.Indeed,it has been observed (retrospectively) that some 
cases of post-transfusion hepatitis В were associated with the trans­
fusion of HBsAg negative/anti-HBc positive blood(Hoofnagle et al., 
1974¡Lander et al.,1978¡Katchaki et al. ,1978).The apparent detection 
of "occult" HBsAg in some of such sera (Table IV) adds to the posi-
tive circumstantial evidence.However,the crucial proof obtained by a 
prospective follow-up of recipients of such blood still has to be 
seen.We feel that - until such proof is obtained in a controlled 
prospective study - it would be premature (both from the epidemiolo-
gical and economic point of view) to advocate the introduction of a 
routine screening of blood donors for anti-HBc,next to the screening 
for HBsAg. 
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SUMMARY 
The results of α pilot study on the prevalence of anti-HBc in 
HBsAg negative volunteer blood donors are presented. 
Two techniques for anti-HBc determination were compared first¡radio-
immunoassay (RIA) and indirect immunofluorescence (IF).In a panel 
of 56 sera with known HBV markers,RIA was found significantly more 
sensitive than IF,with a comparably high specificity. 
Out of 2000 HBsAg negative blood donor sera.tested by RIAf46 (2,3%) 
were found positive for anti-HBc.In 24/24 sera,speci ficιty of the 
positive anti-HBc outcome was confirmed.37/46 (80,4%) anti-HBc po­
sitives were found simultaneously positive for anti-HBs,leaving 
9/2000 (0,4%) blood donors positive solely for anti-HBc. 
Twelve anti-HBc positive donor sera were also tested for "occult" 
HBsAg by RIA,after concent rat ion.They were all found weakly positi­
ve in the screening test.In only one of them (which was positive 
solely for anti-HBc) could the specificity of HBsAg presence be 
confirmed by neutralization with human anti-HDs. 
It is concluded that it would be premature to advocate the intro­
duction of anti-HBc as a routine screening of blood donors,before 
the results of prospective controlled studies of the recipients 
of anti-HBc positive blood demonstrate that this may contribute 
to the reduction of the risk of contracting post-transfusion hepa­
titis B. 
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THE OCCURENCE OF ANT]BODY J^ARKERS OF HEPATITIS b VIRUS INFECTION IN AN 
HBsAg - NEGATIVE BLOOD DONOR POPULATION. 
INTRODUCTION 
The presence in blood of one or more types of antibodies to hepatitis В vi­
rus (HBV) antigenic determinants (anti-HBs.ant '--О. and anti-HBe) can be 
used as serologic evidence of exposure to HBV m i - H B s has been studied most 
extensively in this respect (3,14).This paranetm m s practical value in 
blood transfusion because anti-HBs-positive hlo ' ii considered non-infecti­
ous. 
Anti-HBc was found to be a very sensitUu markor of past HBV infection.but 
also for active replication of riBV (6).Detection of anti-HBc in serum as the 
only HBV marker might thcrpf re indicate the presence of HBV which may lead 
to post-transfusion hepatitis В in recipients of sudi HBsAg-negative blood 
(7,11). 
Anti-HBe has been studied much less in this respect,because,except for rather 
insensitive techniques like immunodiffusion and counterimmunoelectrophoresis, 
no suitable tests were available.Anti-HBe has rfji.|Uently been found in chro­
nic HBsAg-carriers.and its presence has been asso^u.ted with reduction or ab­
sence of infectivity of such persons (l?).Some groups have reported on the 
occurence of anti-HBe in HBsAg-negative person; (?,4,13). 
Frösner et al. have tested 1966 HBsAg-negative blood donors for anti-iijs, 
anti-HBc sud anti-HBe by RIA.Anti-HBe was nut found as a sole HBV marker in 
any of them (b). 
We have studied the prevalence and co-occureni^ of anti-HBs,anti-HBe anJ 
anti-HBc in a population of healthy,HB^Ag-nequLive blood donors.Lit ttoult". 
could be used as an indication for the relative sensitivity of ti-L uiree anti-
bodies as markers of preceding HBV irifprtio , r . H U P all three have been Jeter-
mined by the currently most sensitive techn "s as r<idio-(RIA) and enzyme-
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-immuno-assay (EIA). 
MATERIALS AND METHODS 
HBV markers: HBsAg,anti-HBs and anti-HBc were determined by commercially 
available radioimmunoassays (Ausria II,Ausab and Corab.Abbott Laboratories, 
North Chicago,Π..U.S.Α.).These tests were performed according to the manu­
facturer's instructions. 
Anti-HBe was determined by enzyme-immunoassay developed by Van der Waart et 
al. (15).Briefly,this method consists of preincubation of test samples with 
a fixed amount of HBeAg (or normal human serum as a control).Then,the residu­
al HBeAg activity is tested by transferring the samples to wells of microti-
tration plates,coated with human anti-HBe.After incubation and washing,enzy­
me-labelled anti-HBe is added.Incubation and washing are repeated and enzyme 
-substrate is added.The presence of HBeAg results in a yellow-brown colour. 
Anti-HBe in test samples will partially block the added HBeAg,resulting in a 
reduced absorbance as measured at 492 nm.Samples were considered weakly posi­
tive if between 25-50% blocking was observed and positive if the blocking was 
50% or more. 
Population: Sera from healthy,HBsAg-negative volunteer blood donors from the 
Red Cross Blood Bank Arnhem. 
RESULTS 
We have tested sera from 1087 HBsAg-negative blood donors for the presence of 
anti-HBc.The ones reproducibly positive (25 sera) and a control group of anti-
HBc negative sera (362) were then tested for anti-HBs by RIA and anti-HBe by 
EIA.The results are summarized in Table I. 
With tests giving either a negative or a positive result for the three diffe-
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rent antibodies to HBV.the donor sera can be divided into 8 groups. 
The first four lines (Table I) represent all samples positive for anti-HBc, 
25 in total.Twenty-three of these 25 sera were also positive for anti-HBs; 
17 of those 23 sera were positive for all three parameters.The last four lines 
represent the blood donors negative for both HBsAg and anti-HBc.Of this whole 
group comprising 1062 sera,an at random chosen group of 362 was actually tes-
ted. In this group 7 (1.9%) were found positive for anti-HBs and 2 of these 7 
(0.5%) were unequivocally positive for anti-HBe.In addition,8 other sera (2.2%) 
negative for both anti-HBc and anti-HBs gave between 25 and 50% blocking and 
were regarded as weakly anti-HBe positive. 
The findings were recalculated for the total group of 1062 donors negative for 
anti-HBc and these data are the ones given in the lower part of Table I. 
DISCUSSION 
From Table I it is evident that between 6 and 7% of the donors have one or mo-
re markers indicative of a preceding HBV infection.This is a much higher figu-
re than the one for prevalence of HBsAg (0.15%) in a population of Dutch blood 
donors (10).Of the three antibodies tested,anti-HBs occurs most frequently (4% 
positivity).This finding differs from that of Frösner et al. who reported on 
anti-HBc as the most sensitive marker of a previous HBV infection in their 
blood donors (5). 
It has been reported that transfusion with blood,positive for anti-HBs does 
not lead to an increased incidence of hepatitis В in recipients (1,6).In our 
study,most samples positive for anti-HBs were also found positive for either 
anti-HBc or anti-HBe or both.One may wonder whether the presence of these com­
binations is as harmless as the presence of anti-HBs only.This could be inves­
tigated by performing a prospective follow-up of recipients of such blood. 
Two samples (0.2%) were positive for anti-HBc only.Cases of post-transfusion 
Table I: Occurence of anti-HBc,anti-HBs and anti-HBe in 1087 HBsAg-negative donor sera. 
HBcAg 
ANTIBODIES TO 
HBsAg HBeAg 
NUMBER OF 
DONORS 
PERCENTAGE OF 
DONORS 
+ 
+ 
17 
б 
0 
2 
1.6 
0.5 
0.0 
0.2 
15 
24 
1017 
0.5 
1.4 
2.2 
93.6 
T O T A L S 1087 100.0 
6,15 24 1017 ¡Extrapolated from the results obtained in 362/1062 samples negative for anti-HBc. 
In the original group of 362 samples .respectively 2,5,8 and 347 sera were found.See text under 
"results". 
&. 
weakly positive (inhibition in anti-HBe test between 25% and 50%). 
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hepatitis В have occasionally been reprted in recipients of blood in which 
anti-HBc was the only marker of HBV infection (8,9,Π).In some of such donor 
sera HBsAg can be detected by RIA (apparently serologically specific in a con­
firmation test) after an appropriate concentration procedure (9).However,ιπ 
these studies HBeAg and anti-HBe were only tested with insensitive techniques 
like immunodiffusion or they were not tested at all.A prospective follow-up of 
recipients of blood in which anti-HBc is indeed the only marker of HBV infecti­
on has not been performed yet.The effect of administration of such blood to 
susceptible primates should also be investigated.Only on the basis of results 
of such studies,can it be decided whether a costly routine screening of blood 
donors for anti-HBc should be introduced. 
A calculated 2.2% of the population was negative for both anti-HBc and anti-HBs 
but weakly positive for anti-HBe,giving between 25 and 50% blocking.This finding 
differs from that of Frösner et al. who did not find any donor exclusively posi-
tive for anti-HBe (5). 
The clinical and epidemiological significance of our weakly anti-HBe positive 
group is not clear yet.Study of these aspects will be possible,when sensitive 
test systems like RIA and EIA become more widely available.Such studies might 
include attempts to detect HBsAg by RIA or EIA after a concentration of test 
samples as done in anti-HBc containing ones (9).In second instance,the possible 
infectivity of blood positive for anti-HBe,but negative for other markers may 
be tested in the same manner as proposed for anti-HBc. 
The different results obtained by Frösner et al.(5) and our group may be caused 
by a different epide.iiiological situation,but a further study of the significance 
of antibody markers of hepatitis В virus infection in HBsAg negative blood donors 
is clearly indicated. 
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SUMMARY 
Anti-HBs,anti-HBc and anti-HBe were tested in blood donors (negative for HBsAg) 
by radio-and enzyme-immunoassay.In this population 6.42S of the donors were posi-
tive for at least one type of antibody to HBV:4.0% for anti-HBs,2.3% for anti-HBc 
and 4.3% for anti-HBe.Two sera (0.2%) were exclusively positive for anti-HBc, 
eight sera (2.2%) were weakly positive only for anti-HBe.Further study of such 
samples for infectivity might be of interest. 
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SUMMARY 
The development of techniques for determination of hepatitis В virus (HBV) markers 
in blood donors was surveyed. 
Enzyme inmunoassay (EIA) for screening of HBsAg and a simple method for specificity 
control were developed as an alternative to radioimmunoassay (RIA).In preliminary 
experiments the EIA technique was shown to be comparable in sensitivity to RIA for 
determination of HBsAg. 
Subsequently,the new technique was compared to the reversed passive haemagglutination 
in 65 000 sera in a multicentre trial.It was shown to be significantly more sensitive 
than this latter technique,and the preliminary impression of its comparable sensiti­
vity for HBsAg to that of RIA was confirmed. 
It has been suggested that an additional marker of HBV infection,the antibody to the 
core of HBV (anti-HBc),could be of importance in blood transfusion,supposedly as an 
indication of continuing viral replication even in the absence of detectable HBsAg 
in the donor blood.This hypothesis was supported by demonstration of the presence 
of HBsAg in concentrates of two sera from blood donors who were negative for HBsAg 
in routine screening by RIA,positive for anti-HBc and negative for anti-HBs and 
anti-HBe.In a trial of RIA for anti-HBc in 2000 HBsAg negative blood donors in The 
Netherlands,such result - i.e. a positive finding of anti-HBc as a sole marker of 
HBV infection - was seen in 9 (0,45%) blood donors.This prevalence is about 3-fold 
higher than that of HBsAg in The Netherlands,but the technique used for determina­
tion of anti-HBe in this trial had a relatively low sensitivity.When the newly de­
veloped EIA for anti-HBe was applied to test 1087 HBsAg negative donors,the percen­
tage of solely anti-HBc positives was found to be 0,2%.It is concluded that intro-
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auction of general screening of blood donors for anti-HBc should await until it has 
been demonstrated by controlled prospective trials that there exists a real degree 
of risk of post-transfusion hepatitis В in recipients of such blood. 
In the same trial 2,2% of the donors were found weakly positive for anti-HBe.The epi­
demiological significance of this finding is unclear at the moment.It is proposed 
that this phenomenon be studied further,possibly in the same manner as suggested for 
anti-HBc. 
On the whole we conclude that general application of the currently most sensitive 
methods for determination of HBV markers in blood donors may contribute to an albeit 
minor additional decrease of the incidence of post-transfusion hepatitis,but that 
further significant decrease may be expected from the forthcoming research develop­
ments concerning the aetiological agent(s) of so-called "non-B/non-A" hepatitis. 
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SAMENVATTING 
Eerst werd een overzicht gegeven van technieken die werden ontwikkeld voor de 
bepaling van hepatitis В virus (HBV) "markers" bij bloeddonoren. 
De enzyme-immunoassay (EIA) voor het bepalen van HBsAg en een envoudige methode 
voor de specificiteit's controle zijn ontwikkeld als alternatieven voor de radioimmu­
noassay (RIA).De gevoeligheid van de EIA was ongeveer even groot als die van de RIA. 
Deze nieuwe techniek (EIA) werd vergeleken met de omgekeerde passieve haemagglutina-
tie in een "mul ti center" proef met 65 000 sera.De eerstgenoemde techniek bleek sig­
nificant gevoeliger te zijn.Tevens werd in deze proef bevestigd dat de gevoeligheid 
van de EIA ongeveer gelijk was aan die van de RIA. 
Er zijn aanwijzigingen in de literatuur dat een additionele "marker" van infectie 
met HBV,i.e. antistoffen tegen de "core" van HBV (anti-HBc),als enig kenmerk van he­
patitis B-virusinfectie kan vóórkomen en van belang zou kunnen zijn als indicator 
van een zich voortzettende replicatie van HBV.Wij hebben een soortgelijke waarne-
ming gedaan.Het bleek dat in twee sera die positief waren op anti-HBc en negatief op 
HBsAg,anti-HBs en anti-HBe,na concentratie wel HBsAg kon worden aangetoond. 
In een proef met 2000 sera,die in de RIA negatief waren op HBsAg,werd in 9 sera 
(0,45%) anti-HBc gevonden als enig teken van infectie met HBV.Deze prevalentie is 
ongeveer 3 maal hoger dan die van HBsAg bij bloeddonoren in Nederland.De aantekening 
moet worden gemaakt dat de gevoeligheid van de methodiek voor het bepalen van anti-
HBe als mede-"marker" in deze proef.relatief laag was.Toen een nieuw ontwikkelde 
EIA voor het bepalen van anti-HBe in serum werd gebruikt,werd bij 0,2% van 1087 
HBsAg-negatieve bloeddonoren anti-HBc als enig teken van infectie met HBV gevonden. 
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Hoewel het een zéér aantrekkelijke hypothese lijkt naast onderzoek op HBsAg 
ook onderzoek op anti-HBc,als kenmerk van infectie met HBV.voor screening van 
bloeddonoren toe te passen,moet dit vooralsnog als voorbarig worden gezien. 
Eerst zal een gecontroleerd prospectief onderzoek moeten worden ingesteld naar 
de gevolgen van het toedienen van anti-HBc posititef bloed voor de ontvanger. 
In bovengenoemde proef bleek bij 2,2% van de bloeddonoren anti-HBe aantoonbaar 
te zijn,zij het in geringe concentratie.Welke epidemiologische of klinische be-
tekenis hieraan moet worden toegeschreven,is niet bekend.Het lijkt een goede sug-
gestie verder onderzoek naar de betekenis van anti-HBe in donorbloed te doen, 
te zamen met het voorgestelde prospectieve onderzoek betreffende anti-HBc. 
Als algemene conclusie kan worden gesteld dat de invoering van zeer gevoelige 
en eventueel nieuwe methoden om hepatitis B-virus "markers" op te sporen een bij-
drage kan leveren tot een (weliswaar geringe) vermindering van post-trasfusie he-
patitis.Een werkelijk belangrijke reductie van gevallen van post-transfusie hepa-
titis kan echter pas worden verwacht wanneer meer inzicht zal worden verkregen in 
de etiologie van de "non-B/non-A" hepatitis. 
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DETERMINATION OF HEPATITIS В VIRUS MARKERS 
IN BLOOD DONORS 
J.N. KATCHAKI 
STELLINGEN 
I. 
Sera van bloeddonors waarin anti-HBc als enig kenmerk van infectie met hepatitis В virus is 
aangetoond, dienen, na concentratie, opnieuw op HBsAg te worden onderzocht. 
II. 
Men mag het begrip de énige 'marker' van hepatitis B-virusinfectic alleen bezigen, indien de 
aanwezigheid van andere 'markers' is uitgesloten door toepassing van methodieken van 
tenminste dezelfde (hoge) gevoeligheid. 
III. 
Er dient een gecontroleerd prospectief onderzoek te worden verricht naar het vóórkomen van 
post-transfusie hepatitis В bij ontvangers van anti-Hbc positief bloed. 
IV. 
Het bepalen van antistoffen tegen hepatitis A virus voor diagnostische doeleinden heeft alleen 
zin indien deze gekaraktiseerd kunnen worden als IgM-antistoffen. 
V. 
Het gebruik van de 'LE-cell test' voor de diagnose van gesystematiseerde lupus erythematosus 
is obsoleet. 
VI. 
Isomazide (IHN)-prophylaxe bu oudere personen die een grote operatie dienen te ondergaan, 
uitsluitend vanwege tuberculose in de anamnese, is onvoldoende geïndiceerd en niet zonder 
gevaren. 
Girling D.J., Tubercle, 59,13,1978. 
VII. 
Locale productie van Immunoglobulinen in het centraal zenuwstelsel kan alleen nauwkeurig 
worden aangetoond, indien de concentraties van albumine en Immunoglobulinen in de liquor 
cerebro-spinalis in verband zijn gebracht met die in het bloed. 
Fryden Α., Link H., Norby E., Infection and Immun., 21,852,1978. 
VIII. 
Het verdient aanbeveling bij immuun-pathologisch onderzoek meer gebruik te maken van met 
formaline gefixeerde paraffinecoupes. 
IX 
De laboratoriumaspecten van de klinische immunologie komen alleen optimaal tot uiting 
wanneer kwalitatieve en kwantitatieve onderzoekingen van cellulaire en humorale immuniteit 
geïntegreerd plaatsvinden. 
X. 
Faecesonderzoek op Campylobacter dient in Nederland op 's-rijkskosten te kunnen plaats-
vinden, evenals het onderzoek op Salmonella en Shigella. 
XI 
Een van de belangrijkste apparaten van de klinische bactenoloog is een goed functionerende 
telefoon 


